Satoshi Morita
#148,344
Most Influential Person Now
Researcher
Satoshi Morita's AcademicInfluence.com Rankings
Satoshi Moritacomputer-science Degrees
Computer Science
#7620
World Rank
#8022
Historical Rank
Computational Linguistics
#1552
World Rank
#1569
Historical Rank
Machine Learning
#2870
World Rank
#2906
Historical Rank
Artificial Intelligence
#3164
World Rank
#3211
Historical Rank
Download Badge
Computer Science
Satoshi Morita's Degrees
- PhD Computer Science University of Tokyo
- Masters Computer Science Stanford University
- Bachelors Computer Science University of Tokyo
Similar Degrees You Can Earn
Why Is Satoshi Morita Influential?
(Suggest an Edit or Addition)Satoshi Morita's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. (2010) (4109)
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. (2010) (3811)
- Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer. (2015) (854)
- Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). (2013) (492)
- First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. (2009) (478)
- Human iPS cell-derived dopaminergic neurons function in a primate Parkinson’s disease model (2017) (449)
- Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. (2013) (411)
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. (2019) (378)
- Midterm outcomes in patients with intermediate‐sized hepatocellular carcinoma (2010) (288)
- Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan. (2013) (256)
- Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study. (2020) (242)
- Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. (2015) (238)
- Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease (2012) (233)
- Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial. (2013) (213)
- Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). (2010) (205)
- Combined Survival Analysis of Prospective Clinical Trials of Gefitinib for Non–Small Cell Lung Cancer with EGFR Mutations (2009) (197)
- Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. (2008) (196)
- Frequency of and variables associated with the EGFR mutation and its subtypes (2010) (178)
- Simple and accurate electrocardiographic criteria to differentiate takotsubo cardiomyopathy from anterior acute myocardial infarction. (2010) (164)
- Peripheral Endothelial Function and Cardiovascular Events in High‐Risk Patients (2013) (164)
- Correlation Between Radiographic Classification and Pathological Grade of Portal Vein Wall Invasion in Pancreatic Head Cancer (2012) (160)
- Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study. (2010) (159)
- Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR). (2012) (159)
- Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02 (2009) (154)
- Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G). (2016) (146)
- Inner segment/outer segment junction assessed by spectral-domain optical coherence tomography in patients with idiopathic epiretinal membrane. (2010) (145)
- Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. (2013) (142)
- PREOPERATIVE INNER SEGMENT/OUTER SEGMENT JUNCTION IN SPECTRAL-DOMAIN OPTICAL COHERENCE TOMOGRAPHY AS A PROGNOSTIC FACTOR IN EPIRETINAL MEMBRANE SURGERY (2011) (140)
- Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. (2009) (136)
- Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. (2013) (130)
- Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L. (2016) (129)
- New clinical diagnostic criteria for eosinophilic chronic rhinosinusitis. (2011) (121)
- Association between gait speed as a measure of frailty and risk of cardiovascular events after myocardial infarction. (2013) (121)
- Virtual bronchoscopic navigation combined with ultrathin bronchoscopy. A randomized clinical trial. (2013) (117)
- Antithrombotic drugs are risk factors for delayed postoperative bleeding after endoscopic submucosal dissection for gastric neoplasms. (2013) (115)
- Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. (2017) (114)
- 2015 Japanese Society for Dialysis Therapy: Guidelines for Renal Anemia in Chronic Kidney Disease (2017) (111)
- The impact of visceral obesity on surgical outcomes of laparoscopic surgery for colon cancer (2014) (110)
- Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patients - Fushimi AF Registry. (2017) (107)
- Androgen deprivation therapy prevents bladder cancer recurrence (2014) (105)
- Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009). (2018) (103)
- Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer (2014) (102)
- Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. (2014) (101)
- Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. (2012) (98)
- Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study. (2018) (98)
- Laparoscopic surgery for gastric cancer: a collective review with meta-analysis of randomized trials. (2010) (98)
- Pattern of Lymph Node Metastasis Spread in Pancreatic Cancer (2011) (96)
- A meta-analysis of 18F-Fluoride positron emission tomography for assessment of metastatic bone tumor (2010) (96)
- Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy (2013) (93)
- A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data. (2006) (91)
- Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. (2014) (89)
- Prognostic Factors for Survival After Extended Pancreatectomy for Pancreatic Head Cancer: Influence of Resection Margin Status on Survival (2009) (87)
- Video-assisted thoracoscopic lobectomy versus stereotactic radiotherapy for stage I lung cancer. (2015) (85)
- Comparison of long-term survival outcomes between stereotactic body radiotherapy and sublobar resection for stage I non-small-cell lung cancer in patients at high risk for lobectomy: A propensity score matching analysis. (2014) (84)
- Final 3‐year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second‐line Treatment (2018) (83)
- Efficacy of adjuvant Immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials (2006) (83)
- Prevalence and factors associated with sarcopenia in patients with rheumatoid arthritis (2018) (83)
- The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV (2019) (83)
- Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer (2014) (81)
- High expression of ATP-binding cassette transporter ABCC11 in breast tumors is associated with aggressive subtypes and low disease-free survival (2013) (81)
- Knowledge, attitude and practice regarding dengue among people in Pakse, Laos. (2009) (81)
- Taxane-induced peripheral neuropathy and health-related quality of life in postoperative breast cancer patients undergoing adjuvant chemotherapy: N-SAS BC 02, a randomized clinical trial (2012) (80)
- Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. (2018) (80)
- Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. (2013) (73)
- Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor (2021) (72)
- An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. (2011) (72)
- Short-term results of a randomized study between laparoscopic and open surgery in elderly colorectal cancer patients (2014) (71)
- Quality of life in gastric cancer. (2005) (71)
- Expanded living‐donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5‐5‐500 rule ‐ a retrospective study (2019) (71)
- Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib (2011) (71)
- Stereotactic ablative body radiation therapy for octogenarians with non-small cell lung cancer. (2013) (69)
- Prognostic impact of pancreatic margin status in the intraductal papillary mucinous neoplasms of the pancreas. (2010) (69)
- CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. (2014) (69)
- A multicenter phase II study of salvage photodynamic therapy using talaporfin sodium (ME2906) and a diode laser (PNL6405EPG) for local failure after chemoradiotherapy or radiotherapy for esophageal cancer (2016) (68)
- Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection. (2011) (68)
- Reliability and validity of the Functional Assessment of Chronic Illness Therapy–Spiritual (FACIT–Sp) for Japanese patients with cancer (2004) (68)
- Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan (2016) (67)
- Risk analysis and improvement of strategies in patients who have acute type A aortic dissection with coronary artery dissection. (2013) (67)
- Plasma thioredoxin, a novel oxidative stress marker, in patients with obstructive sleep apnea before and after nasal continuous positive airway pressure. (2008) (67)
- Impact of Operative Blood Loss on Survival in Invasive Ductal Adenocarcinoma of the Pancreas (2011) (66)
- Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. (2012) (64)
- A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy (2013) (64)
- Monitoring EGFR T790M with plasma DNA from lung cancer patients in a prospective observational study (2016) (62)
- Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer. (2014) (61)
- Semaphorin 4D, a lymphocyte semaphorin, enhances tumor cell motility through binding its receptor, plexinB1, in pancreatic cancer (2011) (61)
- Invasion of the Splenic Artery Is a Crucial Prognostic Factor in Carcinoma of the Body and Tail of the Pancreas (2010) (61)
- Safety, Tolerability, and Preliminary Efficacy of the Anti-Fibrotic Small Molecule PRI-724, a CBP/β-Catenin Inhibitor, in Patients with Hepatitis C Virus-related Cirrhosis: A Single-Center, Open-Label, Dose Escalation Phase 1 Trial (2017) (60)
- Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods. (2003) (60)
- S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial (2017) (60)
- Extensive reconstruction of the left anterior descending coronary artery with an internal thoracic artery graft. (2011) (60)
- Recurrence Pattern and Prognosis of Pancreatic Cancer After Pancreatic Fistula (2011) (60)
- Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026. (2018) (59)
- Association of serum interleukin-18 and other biomarkers with disease severity in adults with atopic dermatitis (2012) (59)
- Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial (2012) (59)
- Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. (2009) (58)
- Differences in negative T waves between takotsubo cardiomyopathy and reperfused anterior acute myocardial infarction. (2012) (58)
- Preservation of the Pyloric Ring Has Little Value in Surgery for Pancreatic Head Cancer: A Comparative Study Comparing Three Surgical Procedures (2011) (57)
- Application of the transorally inserted anvil (OrVil™) after laparoscopy-assisted total gastrectomy (2011) (57)
- Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial (2013) (56)
- Risk assessment chart for curability of early gastric cancer with endoscopic submucosal dissection. (2011) (56)
- Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients (2016) (56)
- Low Body Weight Is Associated With the Incidence of Stroke in Atrial Fibrillation Patients - Insight From the Fushimi AF Registry. (2015) (55)
- Matched Pair Analysis to Examine the Effects of a Planned Preoperative Exercise Program in Early Gastric Cancer Patients with Metabolic Syndrome to Reduce Operative Risk: The Adjuvant Exercise for General Elective Surgery (AEGES) Study Group (2014) (55)
- Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. (2018) (54)
- Double-blind, placebo-controlled, randomized phase II study of TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based colorectal cancer chemotherapy-induced oral mucositis (2013) (54)
- Focal liver tumors: characterization with 3D perflubutane microbubble contrast agent-enhanced US versus 3D contrast-enhanced multidetector CT. (2009) (54)
- Effect of Daikenchuto, a Traditional Japanese Herbal Medicine, after Total Gastrectomy for Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. (2015) (53)
- Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. (2011) (53)
- Infiltration of PD-1-positive cells in combination with tumor site PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma (2017) (53)
- NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. (2020) (52)
- Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment (2008) (52)
- Differences in negative T waves among acute coronary syndrome, acute pulmonary embolism, and Takotsubo cardiomyopathy (2012) (52)
- Factors associated with health-related quality-of-life in breast cancer survivors: influence of the type of surgery. (2009) (51)
- Relationship between Overall Survival and Response or Progression‐Free Survival in Advanced Non–Small Cell Lung Cancer Patients Treated with Anti–PD‐1/PD‐L1 Antibodies (2016) (51)
- Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer (2012) (50)
- Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation (2017) (50)
- Clinical Implications of Peritoneal Cytology in Potentially Resectable Pancreatic Cancer: Positive Peritoneal Cytology May Not Confer an Adverse Prognosis (2007) (50)
- Discrepancy Between Disability and the Severity of Low Back Pain: Demographic, Psychologic, and Employment-Related Factors (2006) (49)
- Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) (2015) (48)
- Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of Kanto CML study group (2015) (48)
- Omentum-preserving gastrectomy for advanced gastric cancer: a propensity-matched retrospective cohort study (2013) (48)
- Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study) (2009) (47)
- Open versus Laparoscopic Surgery for Advanced Low Rectal Cancer (2017) (46)
- Long‐term quality of life of donors after living donor liver transplantation (2012) (46)
- Increased graft occlusion or string sign in composite arterial grafting for mildly stenosed target vessels. (2010) (44)
- Gender differences in patients undergoing surgery for acute type A aortic dissection. (2015) (44)
- SNP (–617C>A) in ARE-Like Loci of the NRF2 Gene: A New Biomarker for Prognosis of Lung Adenocarcinoma in Japanese Non-Smoking Women (2013) (44)
- Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial1 (2014) (43)
- Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001) (2015) (43)
- Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma (2007) (43)
- A randomized phase III trial of post-operative adjuvant oral fluoropyrimidine versus sequential paclitaxel/oral fluoropyrimidine; and UFT versus S1 for T3/T4 gastric carcinoma: the Stomach Cancer Adjuvant Multi-institutional Trial Group (Samit) Trial. (2005) (42)
- Association between breast cancer risk and the wild-type allele of human ABC transporter ABCC11. (2010) (42)
- Single-incision laparoscopic surgery using colon-lifting technique for colorectal cancer: a matched case–control comparison with standard multiport laparoscopic surgery in terms of short-term results and access instrument cost (2012) (42)
- Spiritual needs in cancer patients and spiritual care based on logotherapy (2005) (41)
- Injury and pre-hospital trauma care in Hanoi, Vietnam. (2008) (41)
- Positive Outcomes of High Hemoglobin Target in Patients With Chronic Kidney Disease Not on Dialysis: A Randomized Controlled Study (2011) (41)
- A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. (2019) (41)
- Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial. (2015) (41)
- The quality of life questionnaire for cancer patients treated with anticancer drugs (QOL-ACD): Validity and reliability in Japanese patients with advanced non-small-cell lung cancer (2002) (41)
- Doppler ultrasound findings correlate with tissue vascularity and inflammation in surgical pathology specimens from patients with small intestinal Crohn’s disease (2014) (40)
- Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: An open‐label phase 1 study (2018) (40)
- BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes (2018) (40)
- Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents. (2010) (40)
- A pilot study of regenerative therapy using controlled release of recombinant human fibroblast growth factor for patients with pre-collapse osteonecrosis of the femoral head (2016) (40)
- Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study (2018) (39)
- A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002) (2015) (39)
- Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris. (2013) (38)
- Construction and Validation of a Prognostic Index for Patients With Metastatic Pancreatic Adenocarcinoma (2011) (38)
- Randomised phase III study of S-1 alone versus S-1 plus lentinan for unresectable or recurrent gastric cancer (JFMC36-0701). (2016) (38)
- Long-term quality of life after laparoscopic distal gastrectomy for early gastric cancer: results of a prospective multi-institutional comparative trial (2015) (37)
- Sibling cases of moyamoya disease having homozygous and heterozygous c.14576G>A variant in RNF213 showed varying clinical course and severity (2012) (37)
- Surgical outcomes of laparoscopy-assisted gastrectomy versus open gastrectomy for gastric cancer: a case-control study (2012) (37)
- Breathing–swallowing discoordination is associated with frequent exacerbations of COPD (2017) (37)
- Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas (2011) (36)
- Survival of HER2-positive primary breast cancer patients treated by neoadjuvant chemotherapy plus trastuzumab: a multicenter retrospective observational study (JBCRG-C03 study) (2014) (36)
- Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy. (2013) (36)
- Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis (2014) (36)
- WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient (2010) (36)
- Prognostic Significance of Preoperative Neutrophil–Lymphocyte Ratios in Patients with Stage I Non-small Cell Lung Cancer After Complete Resection (2015) (36)
- Knock Out of S1P3 Receptor Signaling Attenuates Inflammation and Fibrosis in Bleomycin-Induced Lung Injury Mice Model (2014) (36)
- Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR‐mutant non–small cell lung cancer: Multicenter, single‐arm, phase 2 trial (ABC Study) (2018) (36)
- Vaginal Douching in Cambodian Women: Its Prevalence and Association With Vaginal Candidiasis (2009) (36)
- Clinical efficacy of Daikenchuto for gastrointestinal dysfunction following colon surgery: a randomized, double-blind, multicenter, placebo-controlled study (JFMC39-0902) (2015) (35)
- Neoadjuvant palbociclib on ER+ breast cancer (N007): clinical response and EndoPredict’s value (2017) (35)
- Wilms tumor 1 peptide vaccination combined with temozolomide against newly diagnosed glioblastoma: safety and impact on immunological response (2015) (35)
- WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial (2013) (35)
- Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. (2012) (35)
- Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D‐first study (2015) (34)
- Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. (2018) (34)
- Relation between hyperinsulinemia and nonculprit plaque characteristics in nondiabetic patients with acute coronary syndromes. (2011) (34)
- Reevaluation of the Effectiveness of Ramosetron for Preventing Postoperative Nausea and Vomiting: A Systematic Review and Meta-Analysis (2013) (34)
- A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor (2011) (34)
- Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. (2021) (34)
- Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. (2018) (34)
- Accuracy of CT Staging of Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy: Cohort Evaluation within a Randomized Phase II Study (2014) (34)
- Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate Cancer. (2019) (34)
- Silent brain infarction and rapid decline of kidney function in patients with CKD: a prospective cohort study. (2010) (33)
- A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer (2014) (33)
- Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial (2018) (33)
- Assessing clinical benefit response in the treatment of gastric malignant ascites with non-measurable lesions: a multicenter phase II trial of paclitaxel for malignant ascites secondary to advanced/recurrent gastric cancer (2011) (33)
- Angiographic outcomes of right internal thoracic artery grafts in situ or as free grafts in coronary artery bypass grafting. (2010) (33)
- Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide (2016) (32)
- Risk Factors for Severe Adverse Effects and Treatment-related Deaths in Japanese Patients Treated with Irinotecan-based Chemotherapy: A Postmarketing Survey† (2013) (32)
- Influence of clinical parameters on quality of life during chemotherapy in patients with advanced non-small cell lung cancer: application of a general linear model. (2003) (32)
- Influence of Food Intake on the Healing Process of Postoperative Pancreatic Fistula After Pancreatoduodenectomy: A Multi-institutional Randomized Controlled Trial (2015) (32)
- A questionnaire survey of physicians' perspectives regarding the assessment of chemotherapy-induced peripheral neuropathy in patients with breast cancer. (2008) (32)
- Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study (2014) (32)
- Health-Related Quality of Life Among Japanese Women With Iron-Deficiency Anemia (2006) (31)
- A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. (2013) (31)
- Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy (2016) (31)
- Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. (2016) (31)
- Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis. (2014) (31)
- Development and validation of a tuberculosis prognostic score for smear-positive in-patients in Japan. (2013) (30)
- Discontinuation of Dasatinib after Deep Molecular Response for over 2 Years in Patients with Chronic Myelogenous Leukemia and the Unique Profiles of Lymphocyte Subsets for Successful Discontinuation: A Prospective, Multicenter Japanese Trial (D-STOP Trial) (2016) (30)
- Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach (2017) (30)
- Efficacy of Adjuvant Chemotherapy Using Oral Fluorinated Pyrimidines for Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials in Japan (2006) (30)
- Field practice study of half‐dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis (2015) (29)
- Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations (2018) (29)
- ASP8273, a mutant-selective irreversible EGFR inhibitor in patients (pts) with NSCLC harboring EGFR activating mutations: Preliminary results of first-in-human phase I study in Japan. (2015) (29)
- Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. (2013) (29)
- A phase I clinical study of a cocktail vaccine of Wilms’ tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma (2018) (29)
- Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis (2018) (28)
- Virtual bronchoscopic navigation without X-ray fluoroscopy to diagnose peripheral pulmonary lesions: a randomized trial (2016) (28)
- Multicenter phase II study of an oral care program for patients with head and neck cancer receiving chemoradiotherapy (2016) (28)
- Phase I Study of a Combination of S-1 and Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer (2004) (28)
- Prediction of the Pathogens That Are the Cause of Pneumonia by the Battlefield Hypothesis (2011) (27)
- Characteristics of suicide attempters with family history of suicide attempt: a retrospective chart review (2009) (27)
- Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial. (2012) (27)
- Long-term outcome of mitral valve repair for infective endocarditis. (2009) (27)
- Clinical and Immunologic Responses to Very Low-Dose Vaccination with WT1 Peptide (5 µg/Body) in a Patient with Chronic Myelomonocytic Leukemia (2007) (27)
- Multicenter phase II study of weekly paclitaxel plus S-1 combination chemotherapy in patients with advanced gastric cancer (2010) (27)
- Differentiation of focal liver lesions using three-dimensional ultrasonography: retrospective and prospective studies. (2010) (27)
- Comparison of Pancreatic Head Resection With Segmental Duodenectomy and Pylorus-Preserving Pancreatoduodenectomy for Benign and Low-Grade Malignant Neoplasms of the Pancreatic Head (2011) (26)
- Clinical and Radiographic Comparison of Influenza Virus-associated Pneumonia among Three Viral Subtypes. (2016) (26)
- Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial (2016) (26)
- Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer (2015) (26)
- Radiofrequency ablation combined with transarterial chemoembolization for subcapsular hepatocellular carcinoma: a prospective cohort study. (2013) (26)
- Carbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies (2017) (26)
- The superiority of the seventh edition of the TNM classification depends on the overall survival of the patient cohort (2013) (26)
- Evidence suggesting that oral corticosteroids increase mortality in stable chronic obstructive pulmonary disease (2014) (26)
- Rectal content and intrafractional prostate gland motion assessed by magnetic resonance imaging. (2011) (26)
- Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). (2015) (26)
- The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ (2014) (26)
- A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). (2010) (25)
- Genotype of thymidylate synthase likely to affect efficacy of adjuvant 5-FU based chemotherapy in colon cancer. (2006) (25)
- Quality of life and nutritional consequences after aboral pouch reconstruction following total gastrectomy for gastric cancer: randomized controlled trial CCG1101 (2016) (25)
- Association of IRF5 Polymorphisms with Susceptibility to Hemophagocytic Lymphohistiocytosis in Children (2011) (25)
- Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study (2014) (25)
- Lifestyle and work predictors of fatigue in Japanese manufacturing workers. (2007) (25)
- A randomized phase III trial exploring the prognostic value of extensive intraoperative peritoneal lavage in addition to standard treatment for resectable advanced gastric cancer: CCOG 1102 study. (2014) (25)
- Novel Lens culinaris agglutinin-reactive fraction of α-fetoprotein: a biomarker of hepatocellular carcinoma recurrence in patients with low α-fetoprotein concentrations (2012) (24)
- Unified approach for extrapolation and bridging of adult information in early-phase dose-finding paediatric studies (2016) (24)
- Detecting overall survival benefit derived from survival postprogression rather than progression-free survival. (2015) (24)
- Preventive effect of goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: a placebo-controlled double-blind randomized phase II study (the GONE Study). (2009) (24)
- Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients (2010) (24)
- 18F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with 18F-FDG PET and immunohistochemistry (2010) (24)
- Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naïve patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102) (2016) (24)
- Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer (2010) (24)
- Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients (2019) (24)
- Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives (2004) (24)
- A multicenter phase II study of biweekly paclitaxel and S-1 combination chemotherapy for unresectable or recurrent gastric cancer (2008) (24)
- "Point of no return (PNR)" in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. (2005) (23)
- Web-based Recruiting for a Survey on Knowledge and Awareness of Cervical Cancer Prevention Among Young Women Living in Kanagawa Prefecture, Japan (2014) (23)
- Clinical Characteristics of Influenza-Associated Pneumonia of Adults: Clinical Features and Factors Contributing to Severity and Mortality (2017) (23)
- A prospective randomized controlled trial of subcutaneous passive drainage for the prevention of superficial surgical site infections in open and laparoscopic colorectal surgery (2014) (23)
- Application of the continual reassessment method to a phase I dose‐finding trial in Japanese patients: East meets West (2011) (23)
- Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation. (2015) (22)
- Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. (2009) (22)
- Carvedilol versus Metoprolol for the Prevention of Atrial Fibrillation After Off-Pump Coronary Bypass Surgery: Rationale and Design of the Carvedilol or Metoprolol Post-Revascularization Atrial Fibrillation Controlled Trial (COMPACT) (2006) (22)
- High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients (2014) (22)
- Wilms tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. (2007) (22)
- Altered expression of major immune regulatory molecules in peripheral blood immune cells associated with breast cancer (2016) (22)
- Lung Adenocarcinoma With MUC4 Expression Is Associated With Smoking Status, HER2 Protein Expression, and Poor Prognosis: Clinicopathologic Analysis of 338 Cases (2017) (22)
- β-Blocker Prescription and Outcomes in Hemodialysis Patients from The Japan Dialysis Outcomes and Practice Patterns Study (2009) (22)
- Differences in Predictive Factors for Sustained Clinical Remission with Abatacept Between Younger and Elderly Patients with Biologic-naive Rheumatoid Arthritis: Results from the ABROAD Study (2016) (22)
- WT1 peptide‐based immunotherapy for advanced thymic epithelial malignancies (2018) (21)
- A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer (2012) (21)
- Risk factors for the severity and mortality of pneumococcal pneumonia: Importance of premorbid patients' performance status. (2016) (21)
- Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. (2012) (21)
- Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study (2013) (21)
- Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome. (2017) (21)
- A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study (2014) (20)
- Diagnostic Value of Computed Tomography for Staging of Clinical T1 Gastric Cancer (2014) (20)
- A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial (2018) (20)
- Prognostic factors in stage IB gastric cancer. (2014) (20)
- A history of smoking is inversely correlated with the incidence of gemcitabine-induced neutropenia. (2009) (20)
- Durable tumor remission in patients with platinum-resistant ovarian cancer receiving nivolumab. (2015) (20)
- Iron and iodine deficiencies among under-2 children, adolescent girls, and pregnant women of Bangladesh: association with common diseases. (2009) (20)
- Evaluation of the efficacy of daikenchuto (TJ -100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial. (2016) (20)
- Association of HLA-A*02:06 and HLA-DRB1*04:05 with clinical subtypes of juvenile idiopathic arthritis (2011) (20)
- A comparison of multimodality treatment: two and four courses of neoadjuvant chemotherapy using S-1/CDDP or S-1/CDDP/docetaxel followed by surgery and S-1 adjuvant chemotherapy for macroscopically resectable serosa-positive gastric cancer: a randomized phase II trial (COMPASS-D trial). (2012) (20)
- Randomized clinical trial of extensive intraoperative peritoneal lavage versus standard treatment for resectable advanced gastric cancer (CCOG 1102 trial) (2019) (19)
- Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer. (2021) (19)
- Randomized phase II study of concurrent versus sequential alternating ge fi tinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations : NEJ 005 / TCOG 0902 (2015) (19)
- Perspectives on the Design of Clinical Trials Combining Transarterial Chemoembolization and Molecular Targeted Therapy (2012) (19)
- Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study (2017) (19)
- Augmentation index is elevated in aortic aneurysm and dissection. (2009) (19)
- A randomized phase II trial to test the efficacy of intra-peritoneal paclitaxel for gastric cancer with high risk for the peritoneal metastasis (INPACT trial). (2011) (18)
- A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G). (2014) (18)
- A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial) (2014) (18)
- Brief Report: Validation Study of the IASLC Histological Grading System of Invasive Lung Adenocarcinoma1. (2021) (18)
- Clinical and immunologic responses to very low-dose vaccination with WT1 peptide (5 microg/body) in a patient with chronic myelomonocytic leukemia. (2007) (18)
- An adaptive power prior for sequential clinical trials – Application to bridging studies (2019) (18)
- International retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-GC-1). (2018) (18)
- TITE‐BOIN‐ET: Time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes (2019) (18)
- Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial) (2018) (18)
- A Methylene Blue–assisted Technique for Harvesting Lymph Nodes After Radical Surgery for Gastric Cancer (2015) (18)
- Identification of Occult Parechymal Disease Such as Emphysema or Airway Disease Using Screening Computed Tomography (2010) (18)
- Arterial graft deterioration one year after coronary artery bypass grafting. (2010) (18)
- S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study (2017) (17)
- Survival Benefit of and Indications for Adjuvant Chemotherapy for Resected Colorectal Liver Metastases—a Japanese Nationwide Survey (2019) (17)
- Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: A propensity score‐based weighting (2015) (17)
- A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110). (2015) (17)
- Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). (2019) (17)
- The impact of age on outcomes of elderly ED patients ventilated due to community acquired pneumonia. (2015) (17)
- Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor. (2012) (17)
- Transcutaneous oxygen pressure as a surrogate index of lower limb amputation. (2016) (17)
- The Long-term Clinical Course of Chronic Eosinophilic Pneumonia. (2016) (17)
- Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari) (2017) (17)
- A prospective, multicentre phase II trial of low-dose erlotinib in non-small cell lung cancer patients with EGFR mutations pretreated with chemotherapy: Thoracic Oncology Research Group 0911. (2015) (16)
- Depression in Japanese Patients With Chronic Obstructive Pulmonary Disease: A Cross-Sectional Study (2013) (16)
- Efficacy of ezetimibe is associated with gender and baseline lipid levels in patients with type 2 diabetes. (2012) (16)
- A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer (2020) (16)
- Combination chemotherapy with S-1 plus cisplatin for gastric cancer that recurs after adjuvant chemotherapy with S-1: multi-institutional retrospective analysis (2011) (16)
- A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109). (2015) (16)
- Clinical pharmacology of daikenchuto assessed by transit analysis using radiopaque markers in patients with colon cancer undergoing open surgery: a multicenter double-blind randomized placebo-controlled study (JFMC39-0902 additional study) (2016) (16)
- Positron emission mammography (PEM): reviewing standardized semiquantitative method (2013) (16)
- Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study (2018) (16)
- Prognostic Factors and Efficacy of First-Line Chemotherapy in Patients with Advanced Thymic Carcinoma: A Retrospective Analysis of 286 Patients from NEJ023 Study. (2018) (16)
- Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies (2019) (16)
- A randomized phase II trial of omentum-preserving gastrectomy for advanced gastric cancer. (2013) (16)
- Serum milk fat globule epidermal growth factor 8 elevation may subdivide systemic lupus erythematosus into two pathophysiologically distinct subsets (2014) (16)
- The domain structure of the EORTC QLQ‐STO22 supported by Japanese validation data (2008) (16)
- A phase I/II study of XELIRI plus bevacizumab as second-line chemotherapy for Japanese patients with metastatic colorectal cancer (BIX study). (2014) (16)
- Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study (2018) (15)
- Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004) (2014) (15)
- Long-Term Outcomes of Hepatic Resection versus Living Donor Liver Transplantation for Hepatocellular Carcinoma: A Propensity Score-Matching Study (2015) (15)
- Physicians' reasons for not entering their patients in a randomized controlled trial in Japan. (2004) (15)
- Combined prognostic utility of white blood cell count, plasma glucose, and glomerular filtration rate in patients undergoing primary stent placement for acute myocardial infarction. (2009) (15)
- Heterogeneity in responsiveness of perceived quality of life to body composition changes between adult- and childhood-onset Japanese hypopituitary adults with GH deficiency during GH replacement. (2007) (15)
- Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients (2018) (15)
- NEJ009 trial: A randomized phase III study of gefitinib (G) in combination with carboplatin (C) plus pemetrexed (P) versus G alone in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) with EGFR mutation. (2014) (15)
- Clinical Outcomes of Second-Line Chemotherapy in Patients with Previously Treated Advanced Thymic Carcinoma: A Retrospective Analysis of 191 Patients from the NEJ023 Study. (2019) (15)
- 9LBA A randomized phase III study comparing gefitinib with carboplatin (CBDCA) plus paclitaxel (TXL) for the first-line treatment of non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ002 study (2009) (15)
- Different learning curves between stent retrieval and a direct aspiration first-pass technique for acute ischemic stroke. (2018) (15)
- Preoperative chemotherapy is effective for stage III resectable non--small-cell lung cancer: metaanalysis of 16 trials. (2013) (15)
- Daikenchuto accelerates the recovery from prolonged postoperative ileus after open abdominal surgery: a subgroup analysis of three randomized controlled trials (2019) (15)
- The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C) (2018) (15)
- Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer. (2013) (14)
- Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects. (2011) (14)
- A Randomized Controlled Trial of Telemedicine for Long-Term Sleep Apnea CPAP Management. (2020) (14)
- A Phase III trial to evaluate the effect of perioperative nutrition enriched with eicosapentaenoic acid on body weight loss after total gastrectomy for T2-T4a gastric cancer. (2012) (14)
- Risk stratification and clinical course of hepatitis B virus reactivation in rheumatoid arthritis patients with resolved infection: final report of a multicenter prospective observational study at Japanese Red Cross Hospital (2019) (14)
- Effect of Daikenchuto (TJ-100) on postoperative bowel motility and on prevention of paralytic ileus after pancreaticoduodenectomy: a multicenter, randomized, placebo-controlled phase II trial (the JAPAN-PD study). (2013) (14)
- INTERNAL LIMITING MEMBRANE CONTRAST AFTER STAINING WITH INDOCYANINE GREEN AND BRILLIANT BLUE G DURING MACULAR SURGERY (2013) (14)
- Quality of Life Improvements in Dialysis Patients Receiving Darbepoetin Alfa (2008) (14)
- Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations. (2018) (13)
- Anthracycline could be essential for triple-negative breast cancer: A randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101. (2019) (13)
- Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer (2011) (13)
- Sleep disordered breathing and metabolic comorbidities across sex and menopausal status in East Asians: the Nagahama Study (2020) (13)
- Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for operable gastric cancer, a randomized Phase II trial (LANDSCOPE trial). (2012) (13)
- A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey (2016) (13)
- Eicosapentaenoic acid (EPA) efficacy for colorectal aberrant crypt foci (ACF): a double-blind randomized controlled trial (2012) (13)
- Dose-Finding Phase I and Pharmacokinetic Study of Capecitabine (Xeloda) in Combination with Epirubicin and Cyclophosphamide (CEX) in Patients with Inoperable or Metastatic Breast Cancer (2008) (13)
- Bayesian population finding with biomarkers in a randomized clinical trial (2017) (13)
- Angiotensin receptor blocker (ARB)–diuretic versus ARB–calcium channel blocker combination therapy for hypertension uncontrolled by ARB monotherapy (2014) (12)
- Comprehensive data of 3,820 patients newly diagnosed with colorectal liver metastasis between 2005 and 2007: report of a nationwide survey in Japan (2018) (12)
- Impact of UGT1A1 genotype upon toxicities of combination with low‐dose irinotecan plus platinum (2016) (12)
- Anemia affects the quality of life of Japanese cancer patients. (2013) (12)
- Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study. (2016) (12)
- Biomarker‐based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation (2014) (12)
- Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following fi (2018) (12)
- Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: a multi-institution survey (2009) (12)
- Diagnostic criteria that can most accurately differentiate allergic bronchopulmonary mycosis from other eosinophilic lung diseases: A retrospective, single-center study. (2016) (12)
- Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. (2015) (12)
- A phase 1 study of oral ASP5878, a selective small-molecule inhibitor of fibroblast growth factor receptors 1–4, as a single dose and multiple doses in patients with solid malignancies (2019) (12)
- Effect of feedback in promoting adherence to an exercise programme: a randomized controlled trial. (2011) (11)
- A prospective multicenter observational study of surgical palliation examining postoperative quality of life in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. (2017) (11)
- Bumetanide, an Inhibitor of Cation-chloride Cotransporter Isoform 1, Inhibits &ggr;-Aminobutyric Acidergic Excitatory Actions and Enhances Sedative Actions of Midazolam in Neonatal Rats (2013) (11)
- Multicenter Phase II Trial of Combination Chemotherapy with Weekly Paclitaxel and 5-Fluorouracil for the Treatment of Advanced or Recurrent Gastric Carcinoma (2007) (11)
- Oral Food Intake Versus Fasting on Postoperative Pancreatic Fistula After Distal Pancreatectomy (2015) (11)
- 9LBA Antitumor activity of ASP8273, an irreversible mutant selective EGFR-TKI, in NSCLC patients with tumors harboring EGFR activating mutations and T790M resistance mutation (2014) (11)
- Evaluation of the chronic obstructive pulmonary disease assessment test in Japanese outpatients (2014) (11)
- A phase II clinical trial to evaluate the effect of paclitaxel in patients with ascites caused by advanced or recurrent gastric carcinoma: a new concept of clinical benefit response for non-measurable type of gastric cancer. (2003) (11)
- Phase II multi-institutional prospective randomized trial comparing S-1 plus paclitaxel with paclitaxel alone as second-line chemotherapy in S-1 pretreated gastric cancer (CCOG0701) (2016) (11)
- Suboptimal Anticoagulant Management in Japanese Patients with Nonvalvular Atrial Fibrillation Receiving Warfarin for Stroke Prevention. (2017) (11)
- Understanding Measurements of Vitality in Patients with Chronic Kidney Disease: Connecting a Quality-of-Life Scale to Daily Activities (2012) (11)
- Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design (2006) (11)
- Posterior wall involvement attenuates predictive value of ST-segment elevation in lead V4R for right ventricular involvement in inferior acute myocardial infarction. (2009) (11)
- Early recurrence of breast cancer after sentinel node navigation surgery: A multicenter prospective study in Japan. (2009) (11)
- Discontinuation Of Dasatinib In Patients With CML Who Have Maintained Complete Molecular Response For At Least One Year: Results From a Prospective Discontinuation (DADI) Trial (2013) (11)
- Non-obese visceral adiposity is associated with the risk of atherosclerosis in Japanese patients with rheumatoid arthritis: a cross-sectional study (2018) (11)
- Phase 2 study of S‐1 and carboplatin plus bevacizumab followed by maintenance S‐1 and bevacizumab for chemotherapy‐naive patients with advanced nonsquamous non–small cell lung cancer (2013) (11)
- Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC (11)
- Higher level at admission and subsequent decline in hemoglobin in patients with acute pulmonary edema. (2014) (11)
- A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial (2018) (11)
- Basal and Ischemia-Induced Transcardiac Troponin Release into the Coronary Circulation in Patients with Suspected Coronary Artery Disease (2013) (10)
- Treatment Rationale and Study Design for Clinical Trial on the Efficacy of UFT/LV for Stage II Colorectal Cancer With Risk Factors for Recurrence (JFMC46-1201). (2015) (10)
- Lidocaine Concentration in Cerebrospinal Fluid after Epidural Administration: A Comparison between Epidural and Combined Spinal-Epidural Anesthesia (2009) (10)
- The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients (2017) (10)
- Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab (2016) (10)
- Adjuvant chemotherapy with tegafur/uracil (UFT) for gastric cancer. A meta-analysis of centrally randomized clinical trials. (2006) (10)
- Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial (2018) (10)
- Validation Study of the International Association for the Study of Lung Cancer Histologic Grading System of Invasive Lung Adenocarcinoma (10)
- A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial (2018) (10)
- Off-pump bilateral internal thoracic artery grafting in patients with left main disease. (2010) (10)
- Hydroxyurea as an inhibitor of hepatitis C virus RNA replication (2010) (10)
- Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations (2018) (10)
- Decreased plasma levels of active glucagon-like peptide-1 in coronary artery disease. (2015) (10)
- A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II). (2018) (10)
- A Phase II Study of Osimertinib Combined With Platinum Plus Pemetrexed in Patients With EGFR-Mutated Advanced Non-Small-cell Lung Cancer: The OPAL Study (NEJ032C/LOGIK1801). (2020) (10)
- Prognostic Implications of Intraoperative Radiotherapy for Unresectable Pancreatic Cancer (2011) (10)
- Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY) (2018) (10)
- The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. (2019) (10)
- Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer (2015) (10)
- Sequential free right internal thoracic artery grafting for multivessel coronary artery bypass grafting. (2012) (10)
- Local control of sphincter‐preserving procedures and abdominoperineal resection for locally advanced low rectal cancer: Propensity score matched analysis (2017) (9)
- Effects of exenatide and liraglutide on 24-hour glucose fluctuations in type 2 diabetes. (2016) (9)
- A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003). (2013) (9)
- Result of HER2 status in Japanese metastatic gastric cancer: Prospective cohort study (JFMC44-1101). (2013) (9)
- A prophylaxis study of acute exacerbation of interstitial pneumonia after lung cancer surgery. (2020) (9)
- Validation of the Patient Neurotoxicity Questionnaire (PNQ) During Taxane Chemotherapy in a Phase III Randomized Trial in Patients with Breast Cancer: N-SAS BC 02 (2006) (9)
- A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells (2018) (9)
- Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study (2013) (9)
- Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (2018) (9)
- A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II) (2012) (9)
- Small, Moderate, and Large Changes, and the Minimum Clinically Important Difference in the University of California, San Diego Shortness of Breath Questionnaire (2014) (9)
- A randomized phase II trial of preoperative exercise to reduce operative risk in gastric cancer patients with metabolic syndrome: adjuvant exercise for general elective surgery (AEGES) study group. (2008) (9)
- Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERA (2020) (9)
- Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase 3 trial (AXEPT). (2021) (9)
- International Retrospective Cohort Study of Conversion Therapy for Stage IV Gastric Cancer 1 (CONVO‐GC‐1) (2021) (9)
- A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027 (2020) (9)
- S-1 and Oxaliplatin Versus Tegafur-uracil and Leucovorin as Postoperative Adjuvant Chemotherapy in Patients With High-risk Stage III Colon Cancer (ACTS-CC 02): A Randomized, Open-label, Multicenter, Phase III Superiority Trial. (2019) (9)
- Proton Pump Inhibitor Use and the Ef fi cacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT) (2021) (9)
- Bayesian dose‐finding phase I trial design incorporating historical data from a preceding trial (2018) (9)
- Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure (2020) (9)
- Preplanned initial safety analysis of ACTS-CC 02 trial: A large randomized phase III trial of SOX versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer. (2012) (8)
- Intake frequency of vegetables or seafoods negatively correlates with disease activity of rheumatoid arthritis (2020) (8)
- Bayesian adaptive patient enrollment restriction to identify a sensitive subpopulation using a continuous biomarker in a randomized phase 2 trial (2016) (8)
- Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size (2017) (8)
- Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy. (2016) (8)
- Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy (2020) (8)
- A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. (2007) (8)
- A randomized phase II trial of capecitabine plus cisplatin (XP) versus S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment versus SP randomized PII trial (XParTS II). (2015) (8)
- [Reliability and validity of the functional assessment of chronic illness therapy-spiritual (FACIT-Sp) Japanese version in cancer patients--a preliminary study]. (2004) (8)
- Glucose-lowering effect of colestimide is associated with baseline HbA1c in type 2 diabetic patients with hypercholesterolemia. (2011) (8)
- Effect of pH adjustment by mixing steroid for venous pain in colorectal cancer patients receiving oxaliplatin through peripheral vein: a multicenter randomized phase II study (APOLLO) (2015) (8)
- Comprehensive data of 3,525 patients newly diagnosed with colorectal liver metastasis between 2013 and 2014: 2nd report of a nationwide survey in Japan. (2018) (8)
- Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial (2020) (8)
- Phase I study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. (2011) (8)
- Hydroxyurea Suppresses HCV Replication in Humans: A Phase I Trial of Oral Hydroxyurea in Chronic Hepatitis C Patients (2010) (8)
- Diagnostic accuracy of 18F-fluoride PET and PET/CT in patients with bone metastases: a systematic review and meta-analysis update (2013) (8)
- Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). (2019) (8)
- Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations (2020) (7)
- Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR (2021) (7)
- Impacts and predictors of cytotoxic anticancer agents in different breast cancer subtypes. (2012) (7)
- SAMIT: A phase III randomized clinical trial of adjuvant paclitaxel followed by oral fluorinated pyrimidines for locally advanced gastric cancer. (2013) (7)
- Analysis of incomplete quality of life data in advanced stage cancer: A practical application of multiple imputation (2005) (7)
- Darbepoetin Alfa in Patients with Advanced CKD without Diabetes: Randomized, Controlled Trial. (2020) (7)
- Planned Safety Analysis of the ACTS‐CC 02 Trial: A Randomized Phase III Trial of S‐1 With Oxaliplatin Versus Tegafur and Uracil With Leucovorin as Adjuvant Chemotherapy for High‐Risk Stage III Colon Cancer (2017) (7)
- Efficacy of continuous versus intermittent subglottic secretion drainage in preventing ventilator-associated pneumonia in patients requiring mechanical ventilation: A single-center randomized controlled trial (2018) (7)
- [Pilot-testing of the Japanese version of the EORTC QLQ-STO22 gastric cancer module]. (2004) (7)
- Treatment Rationale and Design for J‐AXEL: A Randomized Phase 3 Study Comparing Nab‐Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non–Small‐Cell Lung Cancer (2017) (7)
- HIV/AIDS related knowledge and risk behaviors among female sex workers in two major cities of Mongolia. (2007) (7)
- Does afatinib plus bevacizumab combination therapy induce positive conversion of T790M in previously-negative patients? (2018) (7)
- Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial) (2016) (7)
- Randomized phase III trial comparing surgery alone to UFT + PSK for stage II rectal cancer (JFMC38 trial) (2017) (7)
- Recruitment of patients for a clinical trial: factors on the physician side and reasons on the patient side. (2006) (7)
- Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD) (2005) (7)
- Darbepoetin alfa (KRN321) is safe and effective when administered subcutaneously once every 2 or 4 weeks to patients on peritoneal dialysis in Japan (2011) (7)
- Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study) (2020) (7)
- Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study (2019) (7)
- Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902. (2014) (7)
- Phase II study of S-1 in combination with trastuzumab for HER2-positive metastatic breast cancer. (2014) (7)
- Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case (2012) (7)
- Relative age effect on Nobel laureates in the UK (2013) (6)
- The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. (2015) (6)
- A Bayesian hierarchical mixture model for platelet‐derived growth factor receptor phosphorylation to improve estimation of progression‐free survival in prostate cancer (2010) (6)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01 (2020) (6)
- Effect of herbal medicine daikenchuto on oral and enteral caloric intake after liver transplantation: A multicenter, randomized controlled trial. (2018) (6)
- Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study (2021) (6)
- Prognostic factors for patients with metastatic or recurrent thymic carcinoma receiving palliative-intent chemotherapy. (2020) (6)
- Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002). (2016) (6)
- Physicians’ Attitudes towards and Reasons for Participation in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial (2005) (6)
- Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial (2020) (6)
- Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302) (2018) (6)
- Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial (2021) (6)
- Impact of UGT1A1 genotype on the efficacy and safety of irinotecan‐based chemotherapy in metastatic colorectal cancer (2021) (6)
- Individually different "weights" of quality of life assessment in patients with advanced nonsmall-cell lung cancer. (2003) (6)
- A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002) (2015) (6)
- Gastrointestinal tumors, non-colorectal (2012) (6)
- Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan ( (2020) (6)
- Physicians’ Choice in Using Internet and Fax for Patient Recruitment and Follow-up in a Randomized Controlled Trial (2004) (6)
- Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study (2020) (6)
- A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC). (2007) (6)
- Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations (2021) (6)
- Randomized phase II study of WT1 peptide vaccine plus gemcitabine for advanced pancreatic ductal adenocarcinoma (PDAC): Clinical efficacy and immune response. (2016) (6)
- Long‐term outcome of liver resection for colorectal metastases in the presence of extrahepatic disease: A multi‐institutional Japanese study (2020) (6)
- Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B) (2021) (6)
- G06 : A randomized, double-blind, placebo-controlled phase III trial of TSU-68 (orantinib) combined with transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma (2015) (6)
- Detection of atypical data in multicenter clinical trials using unsupervised statistical monitoring (2019) (6)
- Incorporating Historical Data in Bayesian Phase I Trial Design (2015) (6)
- Survival analysis of a prospective multicenter observational study on surgical palliation among patients receiving treatment for malignant gastric outlet obstruction caused by incurable advanced gastric cancer (2020) (6)
- Prognostic Factors for a Composite End‐Point of Renal Outcomes in Patients With Chronic Kidney Disease (2006) (5)
- Patient‐reported symptom burden as a prognostic factor in treatment with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial (2020) (5)
- Multicenter, phase II study of trastuzumab and paclitaxel to treat HER2-positive, metastatic gastric cancer patients naive to trastuzumab (JFMC45-1102). (2013) (5)
- COMPARISON OF GRACE RISK SCORE VERSUS TIMI RISK SCORE ON ANGIOGRAPHIC FINDINGS IN PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME (2010) (5)
- Assessment and data analysis of health-related quality of life in clinical trials for gastric cancer treatments (2006) (5)
- A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. (2018) (5)
- Randomized phase II study of daily and alternate-day administration of S-1 for advanced gastric cancer (JFMC43-1003) (2017) (5)
- Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study (2018) (5)
- Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study (2019) (5)
- The Efficacy of Reduced-dose Dasatinib as a Subsequent Therapy in Patients with Chronic Myeloid Leukemia in the Chronic Phase: The LD-CML Study of the Kanto CML Study Group (2017) (5)
- Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. (2021) (5)
- Exploring Ethnic Differences in Toxicity in Early-Phase Clinical Trials for Oncology Drugs (2014) (5)
- Predictive factors for structural remission using abatacept: Results from the ABROAD study (2018) (5)
- PP47 First line gefitinib versus first line chemotherapy by carboplatin plus paclitaxel in non-small cell lung cancer patients with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group (2009) (5)
- Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study (2016) (5)
- Meta-analysis of two randomized phase III trials (TCOG GI-0801 and ECRIN TRICS) of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer (2019) (5)
- Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients (2015) (5)
- Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study (2019) (5)
- A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer (2020) (5)
- Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (5)
- Clinical validity of the Japanese version of the Functional Assessment of Cancer Therapy-Anemia Scale (2006) (5)
- 4-step, 2-h carboplatin desensitization in Japanese patients with ovarian cancer: a prospective study (2021) (5)
- Japanese Lung Cancer Society Guideline for stage IV non-small cell lung cancer with epidermal growth factor receptor mutations (2021) (5)
- Pemetrexed monotherapy for chemo-naïve elderly (aged ≥80) patients with non-squamous non-small cell lung cancer: results from combined analysis of two single arm phase II studies (HANSHIN002 and 003) (2017) (5)
- Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective randomized phase III study (2014) (5)
- Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL) (2019) (5)
- The role of HLA-matched unrelated transplantation in adult patients with Ph chromosome-negative ALL in first remission. A decision analysis (2013) (5)
- Implications of ST-segment elevation in leads V5 and V6 in patients with reperfused inferior wall acute myocardial infarction. (2012) (5)
- gBOIN‐ET: The generalized Bayesian optimal interval design for optimal dose‐finding accounting for ordinal graded efficacy and toxicity in early clinical trials (2022) (4)
- Psychosocial domain in quality of life as an independent prognostic factor for survival and tumor response in patients with advanced non-small cell lung cancer (NSCLS) (2000) (4)
- A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial (2019) (4)
- Application of a continual reassessment method to a phase I clinical trial of capecitabine in combination with cyclophosphamide and epirubicin (CEX) for inoperable or recurrent breast cancer. (2004) (4)
- A New Statistical Model Identified Two-thirds of Clinical T1 Gastric Cancers as Possible Candidates for Endoscopic Treatment (2015) (4)
- Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer (2021) (4)
- Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis (2020) (4)
- Bayesian Approach to Utilize Historical Control Data in Clinical Trials (2015) (4)
- The Relationship Between Cephalogram Analysis and Oxygen Desaturation Index During Sleep in Patients Submitted for Mandibular Setback Surgery (2018) (4)
- Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study). (2017) (4)
- Phase II Trial of S-1 plus Low-Dose Cisplatin for Unresectable and Recurrent Gastric Cancer (JFMC27-9902 Step2) (2011) (4)
- A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT). (2016) (4)
- ASP8273 tolerability and antitumor activity in tyrosine kinase inhibitor‐naïve Japanese patients with EGFR mutation‐positive non‐small‐cell lung cancer (2018) (4)
- Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment‐free remission (2020) (4)
- Proposal of a novel H category‐based classification of colorectal liver metastases based on a Japanese nationwide survey (2021) (4)
- Practical Application of the Continual Reassessment Method to a Phase I Dose-Finding Trial in Advanced Breast Cancer (2007) (4)
- Oral S-1 and carboplatin plus bevacizumab with maintenance S-1 and bevacizumab for chemo-naive patients (Pts) with advanced non-squamous non-small cell lung cancer (NSCLC). (2012) (4)
- Characteristics of high-echoic objects in the hepatic vessels of patients with cardiopulmonary arrest: a prospective cohort study (2011) (4)
- Estimating Similarity of Dose–Response Relationships in Phase I Clinical Trials—Case Study in Bridging Data Package (2021) (4)
- ST-SEGMENT DEPRESSION IN LEAD AVR COMBINED WITH NO ST-SEGMENT ELEVATION IN LEAD V1 DIFFERENTIATES TAKOTSUBO CARDIOMYOPATHY FROM ANTERIOR ACUTE MYOCARDIAL INFARCTION (2012) (4)
- Does Gefitinib Re-challenge or Treatment Beyond Progression (TBP) Prolong Survival of NSCLC Patients? - Real World Evidence from Gefitinib Treatment Responders (2012) (4)
- Bevacizumab as First-line Treatment for HER2-negative Advanced Breast Cancer: Paclitaxel plus Bevacizumab Versus Other Chemotherapy (2020) (4)
- Clinicopathologic Study of Intrapancreatic Cancer Spread in Carcinoma of the Body and Tail of the Pancreas (2012) (4)
- Impact of Graft Quality and Fluid Overload on Postoperative Massive Ascites After Living Donor Liver Transplantation. (2019) (4)
- Prognostic Impact of Lateral Pelvic Node Dissection on the Survival of Patients in Low Rectal Cancer Subgroups Based on Lymph Node Size (2021) (4)
- Informed Consent in the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial: A Survey of Collaborating Physicians (2006) (4)
- Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan. (2009) (4)
- Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations. (2017) (4)
- Impact of pathological stage and histological subtype on clinical outcome of adjuvant chemotherapy of paclitaxel plus carboplatin versus oral uracil–tegafur for non-small cell lung cancer: subanalysis of SLCG0401 trial (2019) (4)
- Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma (2020) (4)
- The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset. (2014) (3)
- Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC (2019) (3)
- Bayesian dose‐finding phase I trial design incorporating pharmacokinetic assessment in the field of oncology (2018) (3)
- Efficacy of abatacept in patients with rheumatoid arthritis, as assessed by magnetic resonance imaging of bilateral hands (2017) (3)
- Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2. (2019) (3)
- Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes. (2014) (3)
- Protocol for a multi-site, cluster‐randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non‐small‐cell lung cancer: the ENSURE-GA study (2021) (3)
- Prior inferior myocardial infarction has worse early outcomes in patients undergoing coronary artery bypass grafting than prior anterior myocardial infarction. (2009) (3)
- Long-term outcome of a randomized phase III trial exploring the significance of extensive intraoperative peritoneal lavage in addition to standard treatment for ≥ T3 resectable gastric cancer: CCOG 1102. (2018) (3)
- Analysis of tumor infiltrating lymphocytes in HER2-positive primary breast cancer treated with neoadjuvant lapatinib and trastuzumab: The NeoLath study (JBCRG-16). (2016) (3)
- A human epidermal growth factor receptor 2 expression-based approach to neoadjuvant chemotherapy for operable breast cancer. (2010) (3)
- Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia (2013) (3)
- Risk–benefit point of the Model for End‐stage Liver Disease score in patients waiting for deceased‐donor liver transplantation: A single‐center experience (2019) (3)
- A phase II study of pemetrexed in patients with previously heavily treated non-squamous non-small cell lung cancer (HANSHIN Oncology Group 001) (2013) (3)
- Validity of the Japanese version of functional assessment of cancer therapy-gastric (FACT-Ga) and its sensitivity to ascites volume change: a retrospective analysis of Japanese clinical trial participants (2016) (3)
- Clinical Outcomes of Subcutaneous and Visceral Adipose Tissue Characteristics Assessed in Patients Underwent Transcatheter Aortic Valve Replacement (2020) (3)
- A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizmab in patients with metastatic colorectal cancer: The SOFT study. (2013) (3)
- Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus‐eluting stent in real‐world Japanese patients with coronary artery disease (OPERA): Study design and rationale (2014) (3)
- The impact of a negative history of smoking on survival in patients with non-small cell lung cancer detected with clinic-based screening programs. (2012) (3)
- Association of Education and Depressive Symptoms with Tooth Loss (2020) (3)
- Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy (2014) (3)
- O1-9-2Phase I / II study of ASP8273 in patients with non-small-cell lung cancer (NSCLC) harboring EGFR activating mutations (2015) (3)
- Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC). (2020) (3)
- Efficacy and safety of trastuzumab (T-mab) and paclitaxel for T-mab naïve patients with HER2 positive previously treated metastatic gastric cancer (JFMC45-1102). (2013) (3)
- Correlation between docetaxel-induced skin toxicity and the use of steroids and H2 blockers: A multi-institution survey. (2012) (3)
- Phase I/II study of combination therapy of oral fluorinated pyrimidine compound S-1 with low-dose cisplatin in patients with unresectable and/or recurrent advanced gastric cancer: a novel study design to evaluate safety and efficacy. (2004) (3)
- P2-274: Clinical benefits of pemetrexed 500 mg/m2 and 1000 mg/m2 in a randomized phase II study for pretreated patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) (2007) (3)
- Management of Adverse Events Associated with Dasatinib during Early Periods of Therapy in the Treatment of Chronic Myeloid Leukemia -a Clinical Report of Daria-01 Study (2014) (3)
- Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR (2022) (3)
- SAMIT: Preliminary safety data from a 2x2 factorial randomized phase III trial to investigate weekly paclitaxel (PTX) followed by oral fluoropyrimidines (FPs) versus FPs alone as adjuvant chemotherapy in patients (pts) with gastric cancer. (2011) (3)
- Erratum to: Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) (2015) (3)
- 1304 POSTER Can We Detect Any Ethnic Differences in Toxicity in Early Phase Clinical Trials for Anticancer Drugs (2011) (3)
- Recombinant human FGF-2 for the treatment of early-stage osteonecrosis of the femoral head: TRION, a single-arm, multicenter, Phase II trial. (2021) (3)
- Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial (2020) (3)
- Two phase III studies comparing 6 months of either mFOLFOX6 or XELOX with 3 months of the same regimen as adjuvant chemotherapy in patients with completely resected stage III colon cancer (ACHIEVE) or high-risk stage II colon cancer (ACHIEVE-2). (2014) (3)
- Are volume-dependent parameters in positron emission tomography predictive of postoperative recurrence after resection in patients with thymic carcinoma? (2020) (3)
- Factors associated with compliance and non-compliance by physicians in a large-scale randomized clinical trial (2006) (3)
- Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group. (2011) (2)
- Abstract P5-21-07: Phase II study of eribulin in combination with pertuzumab plus trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced or metastatic breast cancer (2018) (2)
- Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study) (2021) (2)
- Adjuvant paclitaxel followed by oral fluoropyrimidines for gastric cancer: Safety data of the factorial phase III SAMIT trial. (2012) (2)
- Impact of sex and histology on the therapeutic effects of fluoropyrimidines and oxaliplatin plus bevacizumab for patients with metastatic colorectal cancer in the SOFT trial. (2020) (2)
- Femoral head collapse rate among Japanese patients with pre-collapse osteonecrosis of the femoral head (2021) (2)
- Differences in disease status between patients with progression after first-line chemotherapy versus early relapse after adjuvant chemotherapy who undergo second-line chemotherapy for gastric cancer: Exploratory analysis of the randomized phase III TRICS trial. (2020) (2)
- Nomogram for overall survival of Japanese patients with bone-metastatic prostate cancer (2014) (2)
- Macroscopic type is a prognostic factor for recurrence-free survival after resection of gastric GIST. (2014) (2)
- 2329 A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36–0701) (2015) (2)
- Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study (2018) (2)
- The utility of bi-weekly eribulin therapy for metastatic breast cancer: A Japanese multicenter phase II study (JUST-STUDY). (2015) (2)
- Impact of local recurrence on cause-specific death after stereotactic body radiotherapy for early-stage non-small cell lung cancer: dynamic prediction using landmark model (2021) (2)
- Overnight fasting before lapatinib administration to breast cancer patients leads to reduced toxicity compared with nighttime dosing: a retrospective cohort study from a randomized clinical trial (2020) (2)
- Multiparametric magnetic resonance imaging facilitates the selection of patients prior to fertility-sparing management of endometrial cancer (2021) (2)
- An individual patient data meta-analysis of the immunochemotherapy using lentinan in patients with advanced gastric cancer (2016) (2)
- Bayesian response adaptive randomization using longitudinal outcomes (2015) (2)
- Efficacy and safety result of trastuzumab (T-mab) and paclitaxel for T-mab naive patients with HER2-positive previously treated advanced or recurrent gastric cancer (JFMC45-1102): Final report. (2014) (2)
- Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis (2020) (2)
- P203 Dual HER2 blockage with lapatinib and trastuzumab for Japanese patients with HER2+ breast cancer (2015) (2)
- Impact of prior intravesical bacillus Calmette-Guerin therapy on the effectiveness of pembrolizumab for patients with metastatic urothelial carcinoma. (2021) (2)
- Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial. (2022) (2)
- Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study (2019) (2)
- Potential predictive markers of chemotherapy for advanced gastric cancer: Biomarker study in GC0301/TOP-002, randomized phase III study of irinotecan plus S-1 versus S-1. (2014) (2)
- Eribulin in combination with pertuzumab plus trastuzumab for HER2-positive advanced or recurrent breast cancer (JBCRG-M03). (2017) (2)
- Truth-telling to Patients with Advanced Cancer: A Comparison between Cancer center, University Hospitals, General City Hospitals, and Private General Practitioners in Japan (2006) (2)
- Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial. (2021) (2)
- Bayesian analysis of longitudinal dyadic data with informative missing data using a dyadic shared-parameter model (2019) (2)
- The impact of early tumor shrinkage on survival in WJOG4407G trial, a randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab in first-line treatment for metastatic colorectal cancer. (2015) (2)
- Correction to: Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial (2020) (2)
- Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/l-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC). (2014) (2)
- Disagreement between patient‐ and physician‐reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first‐line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial (2020) (2)
- Phase III study comparing the effects of carboplatin plus S-1 and carboplatin plus paclitaxel in chemotherapy-naive patients with advanced non-small cell lung cancer: An updated report of the LETS study (WJTOG3605). (2011) (2)
- Laparoscopic Versus Open Surgery for Locally Advanced Rectal Cancer: Five-Year Survival Outcomes in a Large, Multicenter, Propensity Score-Matched Cohort Study (2021) (2)
- Subgroup analyses of randomized phase II study on gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer. (2014) (2)
- Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study (2021) (2)
- Efficacy analyses of a randomized phase III clinical trial of combined therapy with CPT-11/CDDP versus CPT-11 alone in patients with advanced or recurrent gastric cancer refractory to prior S-1 chemotherapy. (2013) (2)
- A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911. (2014) (2)
- Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker-Driven Phase III Trial (2020) (2)
- Pertuzumab retreatment for HER2‐positive advanced breast cancer: A randomized, open‐label phase III study (PRECIOUS) (2022) (2)
- Safety of Silk-elastin Sponges in Patients with Chronic Skin Ulcers: A Phase I/II, Single-center, Open-label, Single-arm Clinical Trial (2021) (2)
- PLS. plenary session (2012) (2)
- EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs). (2019) (2)
- From translational research to a large randomized clinical trial: a long and streanuous way from bench to bedside. (2007) (2)
- Comparison of Long-Term Survival Outcomes Between Stereotactic Body Radiation Therapy and Sublobar Resection for Stage I Non-Small Cell Lung Cancer in High-Risk Operable Patients: Propensity Score Match Analysis (2014) (1)
- Lymph node dissection in thymic carcinomas and neuroendocrine carcinomas. (2021) (1)
- A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer who relapsed after S-1 adjuvant therapy, XP after TS-1 adjuvant failure (XParTS). (2015) (1)
- Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy (2017) (1)
- Progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in advanced/recurrent gastric cancer (AGC) treatment: Individual-patient-data (IPD) based meta-analysis of randomized trials. (2020) (1)
- Dynamic Registration Method with Balancing for Prognostic Factors in Observational Studies (2013) (1)
- Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study). (2013) (1)
- A Continual Reassessment Method With Cohort Size Adaptation Based on Bayesian Posterior Probabilities in Phase I Dose-Finding Studies (2014) (1)
- A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II) (2012) (1)
- A multinational, randomized, phase III trial of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab as second-line therapy for metastatic colorectal cancer: Safety analysis of Asian XELIRI project (AXEPT). (2017) (1)
- Changes in the sexual function of male patients with rectal cancer over a 2‐year period from diagnosis to 24‐month follow‐up: A prospective, multicenter, cohort study (2020) (1)
- Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components. (2017) (1)
- Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy. (2020) (1)
- A semiparametric Bayesian approach to population finding with time‐to‐event and toxicity data in a randomized clinical trial (2019) (1)
- Safety of trastuzumab in HER2-positive primary breast cancer in Japan: Initial safety report for the large-scale cohort study (JBCRG C-01). (2013) (1)
- A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study (2022) (1)
- Abstract P3-14-08: A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer. Kanagawa breast oncology group (KBOG) 1101 study (2013) (1)
- Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR). (2017) (1)
- Prospective observational cohort study of bevacizumab combined with paclitaxel as the first- or second-line chemotherapy for locally advanced or metastatic breast cancer (Study JBCRG-C05: B-SHARE) (2018) (1)
- Phase II Study of S-1 in Combination with Trastuzumab for HER 2-positive Metastatic Breast Cancer (2014) (1)
- Meta-analysis of Patient-level Data on Therapeutic Effects of TJ-14 (Hangeshashinto) for Gastroenterological Cancer Chemotherapy-induced Severe Oral Mucositis with the HANGESHA-G and HANGESHA-Cs : protocol paper (2017) (1)
- Promoter hypermethylation of TMS1 and DAPK were correlated to low chemosensitivity and poor prognosis in patients with recurrent gastric cancer (2005) (1)
- Abstract 3267: Positive T Wave in Lead aVR and No Negative T Wave in Lead V1 Distinguishes Tako-tsubo Cardiomyopathy From Recanalized Anterior Acute Myocardial Infarction (2009) (1)
- Planned safety analysis of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/LV as adjuvant chemotherapy for high-risk stage III colon cancer. (2016) (1)
- Feasibility study of pemetrexed (PEM) plus bevacizumab (BV) as the first-line treatment for elderly advanced or recurrent non-squamous (non-Sq) non-small cell lung cancer (NSCLC): TORG1015. (2013) (1)
- A comparison of postoperative quality of life after open and laparoscopic gastrectomy for early gastric cancer: A multicenter, nonrandomized, controlled study (CCOG 0802). (2013) (1)
- Randomized phase II study of gemcitabine monotherapy versus gemcitabine with an EPA-enriched oral supplement in advanced pancreatic cancer (YCOG001). (2011) (1)
- Meta-analysis of patient-level data on biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer with the TCOG GI-0801 BIRIP and ECRIN TRICS RCTs: protocol paper (2017) (1)
- The Incidence of Pleural Effusion on Dasatinib Treatment Is Associated with CD56 Positive Cell Values One Month after Commencing Dasatinib and Achievement of an Early Molecular Response in Newly Diagnosed Chronic Myeloid Leukemia Patients: Results of a D-First Study (2014) (1)
- No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation (2022) (1)
- Prognostic model for survival in patients with advanced pancreatic cancer receiving palliative chemotherapy. (2015) (1)
- Multiplex genomic profiling of non-small cell lung cancer patients enrolled in the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin (WJOG6611LTR). (2014) (1)
- Prognosis of early breast cancer patients treated with sentinel node biopsy: A prospective study from the Japanese society for sentinel node navigation surgery. (2012) (1)
- Safety and Effectiveness of a Novel Neuroprotectant, KUS121, in Patients with Non-Arteritic Central Retinal Artery Occlusion: An Open-Label, Non-Randomized, First-in-Humans Phase 1/2 Trial (2019) (1)
- A Decision Analysis of Unrelated Hematopoietic Stem Cell Transplantation for Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia In First Remission Who Lack An HLA-Matched Sibling (2010) (1)
- Safety and Antitumor Activity of Repeated ASP3026 Administration in Japanese Patients with Solid Tumors: A Phase I Study (2020) (1)
- A randomized phase II trial comparing docetaxel plus cyclophosphamide with epirubicin plus cyclophosphamide followed by docetaxel as neoadjuvant chemotherapy for hormone receptor-negative breast cancer: Kanagawa Breast Oncology Croup (KBOG) 1101 study. (2013) (1)
- Influence of Sex on€Mortality and Perioperative Outcomes in€Patients Undergoing TAVR (1)
- Mo1798 Daikenchuto (DKT) Helps Improve Postoperative Functional Gastrointestinal Disorder After Total Gastrectomy in Patients With Gastric Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial(JFMC42-1002) (2014) (1)
- Abstract CT218: Wilms′ tumor gene 1 (WT1) peptide-based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer (2014) (1)
- A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer (2020) (1)
- P2.03-045 Updated Results of Phase II, Liquid Biopsy Study in EGFR Mutated NSCLC Patients Treated with Afatinib (WJOG 8114LTR) (2017) (1)
- Female Preponderance in the Discordant Association between Retinopathy and Nephropathy in Patients with Type 2 Diabetes Mellitus (2011) (1)
- P0371 : A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002) (2015) (1)
- P-0244 A Phase I/II Study of Tri-Weekly Xeliri Plus Bevacizumab for Japanese Patients with MCRC as Second-Line Chemotherapy (Bix Study) (2012) (1)
- Clinical trial comparing UFT-PSK combination adjuvant therapy and surgery-alone for Stage II rectal cancer (2017) (1)
- Bevacizumab plus paclitaxel optimization study with interventional maintenance endocrine therapy in advanced or metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 (BOOSTER) trial. (2014) (1)
- Global phase III trial of comparing mXELIRI+BV vs FOLFIRI+Bmab for 2nd line mCRC (AXEPT) Japanese population analysis. (2018) (1)
- A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial. (2019) (1)
- P3.02b-073 A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR): Topic: EGFR Clinical (2017) (1)
- Tu1107 Doppler Ultrasound Findings Correlate With Tissue Vascularity and Inflammation With Surgical Pathology in Small Intestinal Crohn's Disease Lesions: Clinically Silent or Difficult to Reach by Endoscopy (2013) (1)
- Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214 (2021) (1)
- Prospective analysis of UGT1A1 genotyping for predicting toxicities in advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens: Interim safety analysis of a Japanese observational study. (2013) (1)
- Open versus laparoscopic surgery for low rectal cancer: a large multicenter cohort study in Japan. (2016) (1)
- Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (2021) (1)
- Prolonged air leak after reoperative pulmonary resection (with prior ipsilateral chest surgery). (2020) (1)
- Abstract P3-09-07: A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative metastatic breast cancer (KBCRN-B-002 trial) (2020) (1)
- Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial (2021) (1)
- Delayed antigen-specific CD4+ T-cell induction correlates with impaired immune responses to SARS-COV-2 mRNA vaccination in the elderly (2022) (1)
- Co-expression effect of LLGL2 and SLC7A5 to predict prognosis in ERα-positive breast cancer (2021) (1)
- The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer. (2021) (1)
- A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801). (2022) (1)
- Tolerability and antitumor activity of ASP8273 in TKI-naive Japanese subjects with EGFR mutation–positive non-small cell lung cancer. (2017) (1)
- Multi-institutional phase II study on the safety and efficacy of dynamic tumor tracking-stereotactic body radiotherapy for lung tumors. (2022) (1)
- Impact of UGT1A1 genotype on prognosis in Japanese advanced colorectal cancer patients treated by irinotecan-based regimens. (2015) (1)
- A randomized phase 3 study of maintenance therapy with S‐1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S‐1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L) (2020) (1)
- Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study) (2019) (1)
- Effects of IL‐28B gene polymorphism on response to peginterferon plus ribavirin combination therapy for genotype 2 chronic hepatitis C (2013) (1)
- Heterogeneity of the efficacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients: prospective cohort study (2011) (1)
- 2100 Impact of UGT1A1 genotype and irinotecan exposure on outcomes in Japanese patients with advanced colorectal cancer treated by irinotecan-based regimens (2015) (1)
- Impact of sleep-disordered breathing on glucose metabolism among individuals with a family history of diabetes: the Nagahama study. (2020) (1)
- Acute Effects of Oxygen, Continuous Positive Airway Pressure (CPAP) and Noninvasive Positive Pressure Ventilation (NIPPV) on Sleep Apnea in Stable Congestive Heart Failur (2003) (1)
- Efficacy of adjuvant chemotherapy with oral fluorinated pyrimidines for patients with curatively resected gastric cancer. A meta-analysis of centrally randomized controlled clinical trials (2005) (1)
- A Randomised Phase III Clinical trial of Combined Therapy with CPT-11/CDDP versus CPT-11 alone in Patients with advanced or Recurrent Gastric Cancer Resistant to S-1(Trics Study): Safety Analysis (2012) (1)
- P5-13-23: Individualized Treatment Strategies for HER2−Negative Breast Cancer Subtypes. (2011) (1)
- Prognostic factors in patients with advanced thymic carcinoma treated with chemotherapy: A retrospective analysis of 289 patients from NEJ023 Study. (2016) (1)
- A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17) (2021) (1)
- Abstract 8128: Clinical Implications of ST-Segment Elevation in Leads V5-6 in Patients with Reperfused Inferior Wall Acute Myocardial Infarction (2011) (0)
- 1284PRANDOMIZED PHASE II STUDY OF CONCURRENT VERSUS SEQUENTIAL ALTERNATING GEFITINIB AND CHEMOTHERAPY IN PREVIOUSLY UNTREATED NON-SMALL CELL LUNG CANCER (NSCLC) WITH SENSITIVE EGFR MUTATIONS: NEJ005/TCOG0902. (2014) (0)
- OA23.06 Overall Survival (OS) of EGFR Mutation Positive Non-Small Cell Lung Cancer Patients: Real-World Treatment Patterns of 1,660 Japanese Patients (2017) (0)
- Correction to: Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis (2021) (0)
- A multicenter clinical study to determine the feasible initial dose of lenalidomide for maintenance therapy in patients with multiple myeloma following autologous peripheral blood stem-cell transplantation. (2016) (0)
- Abstract P3-13-06: Tailored neoadjuvant endocrine and chemo-endocrine therapy for postmenopausal patients with estrogen receptor-positive human epidermal growth factor receptor 2-negative primary breast cancer (2018) (0)
- Use of molecular signatures of gastric cancers derived from microarray analysis of paraffin-embedded specimens to predict the degree of response to CPT11/S-1 chemotherapy (2008) (0)
- Efficacy study of sequential therapy with anthracycline, taxane, and eribulin in patients with HER2-negative locally advanced breast cancer (JBCRG-17). (2016) (0)
- Abstract CT078: A prospective biomarker study using digital PCR method in EGFR-mutated, advanced lung adenocarcinoma patients treated with afatinib (West Japan Oncology Group 8114LTR) (2016) (0)
- O3–085MULTICENTER PROSPECTIVE STUDY IN ELDERLY PATIENTS TREATED WITH DTX AND BEV FOR ADVANCED NONSQUAMOUS NSCLC: TORG1014 (2013) (0)
- A Phase II Study of Pemetrexed in Chemotherapy-Naive Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003 (2012) (0)
- WEEKLY ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER DURING CHEMOTHERAPY IN A RANDOMIZED PHASE III TRIAL (2004) (0)
- Special Issue for Selected Articles From the ISBS2019: Statistical Innovation and Contribution in the Era of Precision Healthcare (2021) (0)
- CHARACTERISTICS OF SLEEP APNEA IN GENERAL CARDIOLOGY OUTPATIENTS CLINIC IN JAPAN: COMPATIBLE WITH METABOLIC SYNDROME (2008) (0)
- Randomized controlled trial of the significance of combined use with Ninjin’yoeito in CapeOX + Bmab therapy for patients with unresectable advanced/recurrent colorectal cancer (2022) (0)
- the Safety and Efficacy of Deferasirox for the Transplant Patients with Iron Overload (2016) (0)
- Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial. (2019) (0)
- Efficacy and Safety of Brazilian Green Propolis in Biochemically Recurrent Prostate Cancer after Radical Prostatectomy: A Single-Arm Phase II Study (2022) (0)
- Topical Application of TJ-14 (Hangeshashinto) in the Treatment of Chemotherapy-Induced Oral Mucositis: A Radomized, Placebo-Controlled, Double-Blind, Phase II Trial (2012) (0)
- Abstract 4862: ST-Segment Depression in Lead aVR: A Useful Predictor of Impaired Myocardial Reperfusion in Patients With Anterolateral ST-Segment Elevation Acute Myocardial Infarction (2009) (0)
- Effects of Goshajinkigan (TJ-107) for oxaliplatin-induced peripheral neurotoxicity using the functional assessment of cancer therapy/gynecologic oncology group 12-item neurotoxicity questionnaire in a Phase II, multicenter, randomized, double-blind, placebo-controlled trial (2021) (0)
- Truth-telling to patients with advanced cancer in Japan: A comparison between major centers and local hospitals (2004) (0)
- PSS40 RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOWVISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY (2008) (0)
- Reply: To PMID 25661580. (2015) (0)
- Daikenchuto administration for intestinal hypomotility after open abdominal surgery: A pooled analysis of three randomized controlled trials (2017) (0)
- P3–133EVALUATION OF UGT1A1 GENOTYPING FOR PREDICTING INDIVIDUAL TOXICITY OF IRINOTECAN PLUS PLATINUM ANALOG REGIMENS (2013) (0)
- Oral S-1 and Carboplatin Plus Bevacizumab with Maintenance S-1 and Bevacizumab for Chemo-Naïve Patients with Non-Squamous Non-Small-Cell Lung Cancer (2012) (0)
- Effect of virtual bronchoscopic navigation in combination with ultrathin bronchoscopy for diagnosing peripheral pulmonary lesions (2013) (0)
- P2.03-010 Updated Survival Outcomes of NEJ005/TCOG0902, a Randomized PII of Gefitinib and Chemotherapy in EGFR-Mutant NSCLC (2017) (0)
- Pathologic complete response to cisplatin with dose-dense paclitaxel as neoadjuvant chemotherapy for locally advanced cervical cancer: Preliminary results of a multicenter phase II study with additional mutation analysis of adeno/adenosquamous carcinoma. (2013) (0)
- P094 The impact of androgen deprivation therapy on bladder cancer recurrence: Retrospective analysis (2014) (0)
- Truth-telling to patients with advanced cancer in Japan: A comparison between major centers and local hospitals. (2004) (0)
- Abstract P2-15-01: A randomized, multicenter, phase II study evaluating the efficacy of interventional maintenance endocrine therapy with bevacizumab following fixed cycles of bevacizumab plus paclitaxel in advanced/metastatic ER-positive HER2-negative breast cancer: JBCRG-M04 BOOSTER trial (2020) (0)
- Induction of pathologic complete response by long-term neoadjuvant chemotherapy for gastric cancer: Early results of a randomized phase II study—A COMPASS trial. (2013) (0)
- Abstract 8952: ST-Segment Depression in Lead aVR Predicts In-Hospital Adverse Outcomes in Patients With Inferior Wall Acute Myocardial Infarction (2012) (0)
- Silent NK/T Cell Reactions Against Dasatinib during Sustained Deep Molecular Response before Discontinuation Are Associated with Longer Treatment-Free Remission: A Multicenter, Single-Arm, Phase 2 Study (2019) (0)
- RETROSPECTIVE STUDY Prognostic factors in stage IB gastric cancer (2014) (0)
- WS1. the expansion of surgical indication in gastric colorectal cancer drug therapy (2012) (0)
- Methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective randomized phase III study (2014) (0)
- Abstract 8126: ST-Segment Elevation in Lead aVR Strongly Predicts Adverse Outcomes at 1 Year in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (2011) (0)
- Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative postmenopausal breast cancer: an ad hoc analysis of the JBCRG-C06 Safari study. (2022) (0)
- 1951 Impact of lapatinib (La) treatment duration and endocrine therapy (ET) addition on the efficacy of primary dual HER2 blockage with La and trastuzumab (T) for HER2+ breast cancer (BC) patients (2015) (0)
- Diagnosis and treatment of new idiopathic interstitial pneumonias cases: Analysis using the Japanese Registry (2020) (0)
- Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201) (2022) (0)
- Postprogression Survival for Advanced NSCLC (2012) (0)
- Employing multiple-attribute utility technology to evaluate publicity activities for cancer information and counseling programs in Japan. (2021) (0)
- A prospective cohort study to reduce operative risk in stage I gastric cancer patients with metabolic syndrome: Preoperative exercise versus surgery alone. (2013) (0)
- Influence of Sex onMortality and Perioperative Outcomes inPatients Undergoing TAVR (0)
- THREE YEARS FOLLOW UP AND EFFECTS OF DOMICILIARY BILEVEL NONINVASIVE POSITIVE PRESSURE VENTILATION ON SLEEP APNEA IN STABLE HEART FAILURE (2006) (0)
- Risk factors for surgical complications after D2 gastrectomy following neoadjuvant chemotherapy for gastric cancer. (2014) (0)
- Abstract P3-14-05: Randomized phase II study of preoperative docetaxel and cyclophosphamide-containing chemotherapy for luminal-type breast cancer (2013) (0)
- Breathing-swallowing discoordination associated with frequent exacerbation of COPD (2017) (0)
- PREVALENCE OF SLEEP APNEA AND ACUTE EFFECTS OF OXYGEN, CONTINUOUS POSITIVE AIRWAY PRESSURE, AND BILEVEL NONINVASIVE POSITIVE PRESSURE VENTILATION ON SLEEP APNEA IN PERSISTENT OR PERMANENT ATRIAL FIBRILLATION (2006) (0)
- Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L). (2019) (0)
- Long-Term Survivors in Non-Small Cell Lung Cancer (NSCLC) Patients with Epidermal Growth Factor Receptor (EGFR) Mutations: Data from a Randomized Phase III Study Comparing GEFITINIB with Carboplatin Plus Paclitaxel (NEJ002) (2012) (0)
- MP03-07 IMPACT OF PRIOR INTRAVESICAL BACILLUS CALMETTE-GUERIN THERAPY FOR NON-MUSCLE INVASIVE BLADDER CANCER ON THE EFFICACY OF PEMBROLIZUMAB IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA (2022) (0)
- Abstract 304: Predictive factors of pathological complete response by neoadjuvant chemotherapy for operable breast cancer (2011) (0)
- Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSI) resistance in advanced EGFR-mutant NSCLC: A phase II study (ABCD-study). (2022) (0)
- A Phase I/II Trial of Erlotinib S-1 Therapy in Patients with Previously Treated Non-Small-Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0808/0913 (2012) (0)
- P118 Clinical usefulness of liquid-based cytology in hormone receptor analysis for fine needle aspiration specimens of breast cancer patients (2011) (0)
- Proton Pump Inhibitor Use and the Efficacy of Capecitabine and Fluorouracil in Metastatic Colorectal Cancer: A Post Hoc Analysis of the AXEPT Randomised Phase III Trial (2020) (0)
- O1-13-6Introduction of clinical sequence using a comprehensive cancer gene panel (OncoPrime) to daily clinical practice (2015) (0)
- Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19) (2021) (0)
- GREATER ST-SEGMENT ELEVATION IN LEAD AVR IS ASSOCIATED WITH WORSE OUTCOMES IN PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME (2011) (0)
- the treatment response to eribulin chemotherapy in breast cancer using tumor-infiltrating (2016) (0)
- OS1. gastric cancer (2012) (0)
- A Multi-institutional Phase II Study of Dynamic Tumor Tracking IMRT for Locally Advanced Pancreatic Cancer (2020) (0)
- Comprehensive biomarker analyses identifies HER2, EGFR, MET RNA expression and thymidylate synthase 5'UTR SNP as predictors of benefit from S-1 adjuvant chemotherapy in Japanese patients with stage II/III gastric cancer (2019) (0)
- 11 TRANSLATIONAL RESEARCH TO CLINICAL TRIAL ( RD ) for future Phase II studies to evaluate the effi cacy of the treatment (2007) (0)
- A multicenter phase 2 study of irinotecan (CPT-11) and doxifluridine (5'-DFUR), an intermediate form of capecitabine, for metastatic colorectal cancer (MCRC) (2005) (0)
- Efficacy of daikenchuto for the intestinal hypomotility after open abdominal surgery: A pooled analysis of three randomized controlled trials. (2018) (0)
- A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study (2014) (0)
- Randomized phase II study of mixing steroid to reduce venous pain in patients with colorectal cancer receiving oxaliplatin through peripheral vein (APOLLO study). (2013) (0)
- Optimal dose selection accounting for patient subpopulations in a randomized Phase II trial to maximize the success probability of a subsequent Phase III trial (2018) (0)
- Recombinant Human Fibroblast Growth Factor-2 Treatment to Prevent Femoral Head Collapse in Patients With Osteonecrosis of the Femoral Head: Trion, a Single-Arm, Historical Control, Multicenter, Phase II Trial (2021) (0)
- Long-Term Effects of Domiciliary Bilevel Noninvasive Positive Pressure Ventilation (NPPV) on Sleep Apnea, Cardiac Function and Sympathetic Nervous Activity in Stable Congestive Heart Failure (2004) (0)
- P3.02b-086 ASP8273 Tolerability and Antitumor Activity in TKI-Naïve Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results: Topic: EGFR Clinical (2017) (0)
- Survival impact of post-progression chemotherapy (post-Cx) in advanced gastric cancer (AGC): Systematic review and meta-analysis. (2018) (0)
- Evaluation of the efficacy of daikenchuto (TJ-100) for the prevention of paralytic ileus after pancreaticoduodenectomy: A multicenter, double-blind, randomized, placebo-controlled trial (2016) (0)
- Updated analysis and exploratory analysis of primary tumor location in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment for metastatic colorectal cancer. (2018) (0)
- Title Long-term outcomes of hepatic resection versus living donor liver transplantation for hepatocellular carcinoma : a propensity score-matching study (2019) (0)
- Abstract P6-06-20: Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study) (2013) (0)
- Subset analysis of COMPASS: A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally advanced gastric cancer. (2015) (0)
- O2–089NOMOGRAM FOR PREDICTION OF TOXICITIES IN ADVANCED COLORECTAL CANCER (aCRC) TREATED WITH IRINOTECAN (IRI)-BASED REGIMENS (2013) (0)
- Predicting the efficacy of nivolumab combined with radiation therapy by longitudinal liquid biopsy with artificial intelligence for patients with metastatic breast cancer (translational research of the KBCRN-B-002 trial). (2020) (0)
- Abstract 8134: Differences in Electrocardiographic Findings Between Takotsubo Cardiomyopathy and Reperfused Non-Q-Wave Anterior Acute Myocardial Infarction (2011) (0)
- Postprogression Survival for First-Line Chemotherapy in Patients with Advanced Gastric Cancer (2012) (0)
- Effects of One Month of Domiciliary Noninvasive Positive Pressure Ventilation on Sleep Apnea and Cardiac Function in Stable Congestive Heart Failur (2003) (0)
- Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin‐based or irinotecan‐based therapy for colorectal cancer (2021) (0)
- Abstract P2-15-12: Effect of Bevacizumab and Eribulin for metastatic breast cancer in the real world evaluated using the propensity score matching analysis (PSMA) and inverse probability of treatment weighting analysis (IPTWA) (2020) (0)
- Phase I study of a combination of s-1 and weekly paclitaxel in patients with advanced or recurrent gastric cancer. (2005) (0)
- Laparoscopic Colorectal Cancer Surgery by a Colon Lifting-up Technique That Decreases the Number of Access Ports: Comparison by Propensity Scoring of Short-term and Long-term Outcomes With Standard Multiport Laparoscopic Surgery (2012) (0)
- First-line Gemcitabine Versus Treatment of Physician’s Choice for Metastatic Breast Cancer: A Prospective Cohort Study (2021) (0)
- Abstract P5-11-13: Outcomes of fulvestrant therapy among Japanese women with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of the JBCRG-C06 safari study (2020) (0)
- PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy. (2016) (0)
- ONE MONTH EFFECTS OF OXYGEN THERAPY ON SLEEP APNEA, CARDIAC FUNCTION, AND SYMPATHETIC NERVOUS ACTIVITY IN CHRONIC ATRIAL FIBRILLATION (2007) (0)
- O2-7-1Garenoxacin (GRNX) for secondary prophylaxis against febrile neutropenia (FN) in chemotherapies for advanced lung cancer (2015) (0)
- Contents Vol. 79, 2010 (2011) (0)
- Abstract 10406: The Development of Negative T Waves After Initial ST-Segment Elevation Differs Between Takotsubo Cardiomyopathy and Reperfused Anterior Acute Myocardial Infarction (2010) (0)
- 1955 Primary systemic therapy by dual HER2 blockage with lapatinib (La) + trastuzumab (T) for Japanese patients (pts) with HER2+ breast cancer (BC): Association of La toxicity and dose with treatment efficacy (2015) (0)
- admitted withi n6ho fsymptom onset. Further studies in larger numbers of patients are needed to verify our results. (2010) (0)
- Abstract 14219: Efficacy and Safety of Direct Oral Anticoagulants in Patients With Atrial Fibrillation in the Real-world: The Fushimi AF Registry (2016) (0)
- Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study (2017) (0)
- Abstract P3-12-01: Addition of capecitabine to maintenance endocrine therapy after induction therapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214) (2020) (0)
- MP35-15 DEVELOPMENT AND VALIDATION OF A NOVEL PROGNOSTIC MODEL FOR PREDICTING OVERALL SURVIVAL IN TREATMENT NAIVE CASTRATION-SENSITIVE METASTATIC PROSTATE CANCER. (2018) (0)
- Clinical results of dynamic tumor-tracking stereotactic body radiotherapy with real-time monitoring for liver tumors using a gimbal-mounted linac: A multi-institutional phase II study. (2022) (0)
- Abstract 4860: A Simple Electrocardiographic Criterion for Differentiating Tako-tsubo Cardiomyopathy From Anterior Acute Myocardial Infarction (2009) (0)
- Comparison of Long-term Survival Outcomes Between Stereotactic Body Radiation Therapy and Sublobar Resection for Stage I Non-Small Cell Lung Cancer in High-Risk Operable Patients: Propensity Score-Match Analysis: Early-Stage Non-Small Cell Lung Cancer (2014) (0)
- Abstract P5-11-11: Influence of the adjuvant hormonal therapy on hormone sensitivity and survival outcomes in ER+ and HER2−advanced breast cancer: A subgroup analysis of the JBCRG-C06 Safari study (2020) (0)
- Abstract 5706: Gene expression profile of peripheral blood mononuclear cells in breast cancer patients may be contribute to the identification and the immunological classification of breast cancer patients by blood test (2017) (0)
- The authors respond. (2015) (0)
- Shorter duration of first-line chemotherapy reflects poorer outcomes in patients with HER2-negative advanced breast cancer: a multicenter retrospective study (2021) (0)
- Abstract P4-10-33: Alteration of the tumor immune microenvironment signatures by nivolumab combined with radiation therapy for patients with metastatic breast cancer (Translational Research of the KBCRN-B-002 trial) (2020) (0)
- Phase II Trial of Single-Agent Pemetrexed in Chemonaive Elderly Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) and its Accrual Rate in a Community-Based Clinical Trial Group: LCEN1001 (2012) (0)
- Subject Index Vol. 79, 2010 (2011) (0)
- Multicenter phase II study of oral care program for head and neck cancer patients treated with chemoradiotherapy. (2015) (0)
- Abstract OT3-1-01: A randomized phase II study of maintenance hormone therapy with or without capecitabine after induction chemotherapy with bevacizumab plus paclitaxel in hormone receptor positive and HER2 negative metastatic breast cancer (KBCSG-TR1214) (2013) (0)
- LONG-TERM EFFECTS OF BILEVEL NONINVASIVE POSITIVE PRESSURE VENTILATION ON SLEEP APNEA AND HEART RATE VARIABILITY IN STABLE CONGESTIVE HEART FAILURE (2005) (0)
- Prognostic implication of intraoperative radiotherapy for unresectable pancreatic cancer. (2011) (0)
- International Primary Care Airway Guideline for Chronic Obstructive Pulmonary Disease and Screening Questionnaire for Japanese Subjects (2016) (0)
- First-line gemcitabine versus treatment of physician’s choice in patients with metastatic and stage IV breast cancer: A prospective cohort study. (2014) (0)
- An internally and externally validated nomogram to predict severe neutropenia in Japanese patients (pts) with advanced colorectal cancer (aCRC) treated with irinotecan (IRI)-based regimens. (2014) (0)
- Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study (2022) (0)
- Survival of second-line irinotecan-based chemotherapy in early relapse patients with gastric cancer after adjuvant chemotherapy: Exploratory subgroup analysis of TRICS trial. (2018) (0)
- Abstract P2-11-07: Duration of fasting before taking lapatinib is associated with skin toxicity in neoadjuvant treatment of HER2 positive breast cancer: A cohort study from JBCRG-16/Neo-LaTH (2017) (0)
- ST-SEGMENT DEPRESSION IN LEAD AVR STRONGLY PREDICTS ADVERSE OUTCOMES IN PATIENTS WITH ANTEROLATERAL ST-SEGMENT ELEVATION ACUTE MYOCARDIAL INFARCTION (2012) (0)
- Second-line chemotherapy efficacy in patients with previously treated advanced thymic carcinoma: A retrospective analysis of 192 patients from NEJ023 Study. (2016) (0)
- QOLP-07. HEALTH-RELATED QUALITY OF LIFE AND SYMPTOM BURDEN IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA TREATED WITH BEVACIZUMAB BEYOND PROGRESSION: A PROSPECTIVE TRIAL (2020) (0)
- PROGNOSTIC AND PREDICTIVE FACTORS OF THE RESPONSE TO ADJUVANT CHEMOTHERAPY IN RESECTABLE GASTRIC CANCER: RESULTS FROM THE GASTRIC META-ANALYSIS (2011) (0)
- Statistical Contribution to Quality of Life (QOL) Evaluation (2001) (0)
- Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts). (2016) (0)
- Final Analysis of Randomized Phase III Study WJOG4007 Comparing Irinotecan (CPT-11) with weekly Paclitaxel (WPTX) in advanced Gastric Cancer (AGC) Refractory to Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP) (2012) (0)
- Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study (2022) (0)
- Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study. (2013) (0)
- Clinical trials of WT1 peptide vaccine to gynecologic malignancies that are resistant to conventional therapies. (2010) (0)
- Randomized Phase III Study of Irinotecan (CPT-11) Versus Weekly Paclitaxel (WPTX) for Advanced Gastric Cancer (AGC) Refractory to Combination Chemotherapy (CT) of Fluoropyrimidine Plus Platinum (FP): WJOG4007 Trial (2012) (0)
- Retrospective Efficacy and Safety Analysis of Erlotinib (E), Pemetrexed (P) and Docetaxel (D) in Previously Treated Non-Small-Cell Lung Cancer Patients (NSCLC) without EGFR Mutation (2012) (0)
- Bayesian decision theory for clinical trials: Utility and sample size determination (2020) (0)
- O2-4-3Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC): 1,660 Japanese patients (pts) (2016) (0)
- Effects of One Month of Domiciliary NIPPV on Sleep Apnea and Cardiac Function in Stable Congestive Heart Failure (2003) (0)
- 2226 Feasibility of weekly intraperitoneal versus intravenous paclitaxel delivered from the day of radical surgery for gastric cancer: A preliminary safety analysis of INPACT study, a randomized controlled trial (2015) (0)
- TJ-107 for the prevention of oxaliplatin-induced peripheral neuropathy: Results of a phase II randomized placebo-controlled clinical trial. (2012) (0)
- Randomized Phase II Study of Concurrent Gefitinib Plus Chemotherapy Versus Alternation of Gefitinib and Chemotherapy in Previously Untreated Non-Small Cell Lung Cancer (NSCLC) with Sensitive EGFR Mutations: NEJ005/TCOG0902 (2012) (0)
- Dynamic treatment regimen analysis to determine which treatment sequence can prolong survival of NSCLC patients. (2013) (0)
- Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trial (2012) (0)
- Possible aids to remove the burdens during informed consent process in clinical trials: A case of National Surgical Adjuvant Study of Breast Cancer 02 (N-SAS BC 02). (2004) (0)
- Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components (2018) (0)
- Correction to: Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study (2020) (0)
- Oral Communication VI: Liver, Gastrointestinal Tract and CancerOR53: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Extract of Herbal Medicine Daikenchuto to Prevent Bowel Dysfunction After Adult Liver Transplantation (2017) (0)
- What Factors Affect Long-Term Survival After Responding to Gefitinib in Advanced Non-Small-Cell Lung Cancer? Real World Evidence (2012) (0)
- [BIOSTATISTICS FOR CANCER CLINICAL TRIALS]. (2015) (0)
- O1-19-5A new approach to collecting biobank and bioinformatics data at Kyoto University Cancer Center (2015) (0)
- Possible aids to remove the burdens during informed consent process in clinical trials: A case of National Surgical Adjuvant Study of Breast Cancer 02 (N-SAS BC 02) (2004) (0)
- Abstract A165: Result of a phase 1 (dose-escalation stage), first-in-human study of ASP5878, an oral FGFR inhibitor, in patients with advanced solid tumors (2015) (0)
- Early results of a randomized phase II, compass trial to compare regimen and duration of neoadjuvant chemotherapy for gastric cancer. (2013) (0)
- The 2020 Edition of the Clinical Guidelines for Lung Cancer: Challenges and Future Perspectives (2021) (0)
- Abstract P4-14-07: Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 8–12 weeks' exemestane exposure for ER+/HER2– postmenopausal breast cancer patients (2019) (0)
- A randomized 2X2 phase II trial comparing two and four courses of S-1/cisplatin (SC) and paclitaxel/cisplatin (PC) as neoadjuvant chemotherapy for locally resectable advanced gastric cancer: Survival results of COMPASS. (2015) (0)
- Clinical efficacy of carbapenems on hospital-acquired pneumonia in accordance with the Japanese Respiratory Society Guidelines for management of HAP (2011) (0)
- Abstract 13858: Early Hemoglobin Decrease in Heart Failure With Acute Pulmonary Edema (2013) (0)
- Long-Term Follow up of a Feasibility Study of the Factorial Phase III Samit Trial: Adjuvant Paclitaxel Followed by S1 for Gastric Cancer (2012) (0)
- Overall Survival Analysis of Bevacizumab Plus Erlotinib for Advanced EGFR-Mutant Metastatic NSCLC (2021) (0)
- P30-10 Prevention of chemotherapy-induced peripheral neuropathy by compression therapy (2021) (0)
- S-1 and oxaliplatin versus tegafur-uracil and leucovorin as post-operative adjuvant chemotherapy in patients with high-risk stage III colon cancer: updated 5-year survival of the phase III ACTS-CC 02 trial (2021) (0)
- The efficacy and safety of FOLFIRI+BEV/mXELIRI+BEV by UGT1A1 polymorphisms in metastatic colorectal cancer AXEPT trial (2019) (0)
- PCN68 QUALITY OF LIFE OF PATIENTS RECEIVING ADJUVANT CHEMOTHERAPIES FOR BREAST CANCER IN JAPAN (2006) (0)
- Abstract OT2-07-05: A phase III trial to compare eribulin mesylate + trastuzumab (H) + pertuzumab (P) with paclitaxel or docetaxel + HP for HER2-positive advanced or metastatic breast cancer (JBCRG-M06/ EMERALD) (2019) (0)
- Title Study protocol of the TRICOLORE trial : A randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1 , irinotecan , and bevacizumab as first-line therapy for metastatic colorectal cancer (2018) (0)
- What factors affect long-term survival after responding to gefitinib in advanced non-small cell lung cancer? Real-world evidence. (2012) (0)
- Harvesting lymph nodes in gastric cancer surgery: A prospective randomized controlled study. (2014) (0)
- A multidisciplinary treatment comprising standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for Ewing sarcoma family of tumor (ESFT) in Japan: Results of the first Japan Ewing Sarcoma Study (JESS) 04. (2012) (0)
- O1-9-2TUMOR GENOMIC PROFILING OF NSCLC FROM THE PHASE III TRIAL OF FIRST-LINE S-1/CBDCA VERSUS PACLITAXEL/CBDCA (WJOG6611LTR) (2014) (0)
- Abstract OT1-3-01: Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components (2015) (0)
- Abstract 4861: Prolonged QRS Duration is a Strong Predictor of Adverse Outcomes in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (2009) (0)
- Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases (2020) (0)
- Correction to: Optimal Decision Criteria for the Study Design and Sample Size of a Biomarker‑Driven Phase III Trial (2020) (0)
- Abstract P5-16-04: A randomized phase II neoadjuvant study comparing docetaxel and cyclophosphamide (TC) with 5-fluorouracil, epirubicin, and cyclophosphamide followed by docetaxel (FEC-D) for hormone receptor-negative breast cancer: The Kanagawa breast oncology group (KBOG) 1101 study (2017) (0)
- A survival analysis of a prospective multicenter observational study of surgical palliation in patients treated for malignant gastric outlet obstruction caused by incurable advanced gastric cancer. (2018) (0)
- IS7. lung cancer (2012) (0)
- ASP2215 in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia: Preliminary Results from a Phase 1 Open-Label, Dose-Escalation Study (2015) (0)
- Dissection of the lateral lymph nodes with short axis of ≥ 5 mm affects the prognosis in rectal cancer patients: A central review of 738 lower rectal cancer magnetic resonance images. (2019) (0)
- Title High testosterone levels in prostate tissue obtained by needle biopsycorrelate with poor-prognosis factors in prostate cancer patients (2019) (0)
- Clinical Trial Note Application of a Continual Reassessment Method to a Phase I Clinical Trial of Capecitabine in Combination with Cyclophosphamide and Epirubicin (CEX) for Inoperable or Recurrent Breast Cancer (2004) (0)
- A phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis: Induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (IDREAM) study (2021) (0)
- High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients (2014) (0)
- Heterogeneity of the ef fi cacy of the 23-valent pneumococcal polysaccharide vaccine caused by various underlying conditions of chronic pulmonary disease in older patients : prospective cohort study (0)
- A Multi-institutional Phase II Study of Dynamic Tumor Tracking SBRT for the Lung (2020) (0)
- Factors associated with overall survival after recurrence in patients with ER-positive/HER2-negative breast cancer: An ad-hoc analysis of the JBCRG-C06 Safari study (2021) (0)
- Phase II study on radiofrequency ablation in early breast cancer. (2016) (0)
- Final results of the ACTS-CC 02 trial: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer. (2021) (0)
- Differential association of proton pump inhibitors with efficacy of capecitabine and 5-fluorouracil in metastatic colorectal cancer: A post-hoc analysis from AXEPT phase III trial. (2020) (0)
- Construction and validation of a practical prognostic index for patients with metastatic pancreatic adenocarcinoma. (2011) (0)
- MP45-04 ANDROGEN DEPRIVATION THERAPY PREVENTS RECURRENCE OF BLADDER CANCER (2015) (0)
- ACTR-04. BIOMARK: A PHASE II STUDY OF BEVACIZUMAB BEYOND PROGRESSION FOR NEWLY DIAGNOSED GLIOBLASTOMA: SAFETY, EFFICACY AND PROSPECTIVE BIOMARKER ANALYSIS (2019) (0)
- Androgen deprivation therapy to prevent bladder cancer recurrence. (2015) (0)
- LATERAL ST-SEGMENT ELEVATION IS A STRONG PREDICTOR OF IMPAIRED MYOCARDIAL REPERFUSION IN PATIENTS WITH INFERIOR ACUTE MYOCARDIAL INFARCTION (2010) (0)
- TRUSTY: A randomized multicenter phase II/III study of trifluridine/tipiracil and bevacizumab versus irinotecan, fluoropyrimidine, and bevacizumab as second-line treatment in patients with metastatic colorectal cancer progressive during or following first-line oxaliplatin-based chemotherapy. (2018) (0)
- TCT-143 Twelve-Month Clinical Outcomes from the Optimal Duration of Dual Antiplatelet Therapy Following Treatment with Endeavor (Zotarolimus-Eluting Stent) in Real-World Japanese Patients with Coronary Artery Disease (OPERA) Study (2013) (0)
- Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancer (2022) (0)
- Erratum to: Outcomes of trastuzumab therapy in HER2‑positive early breast cancer patients (2015) (0)
- Abstract 8928: ST-Segment Elevation in Lead aVR is the Strongest Predictor of Severe Left Main or 3-Vessel Disease in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (2010) (0)
- [Planning, administration, and management of the clinical trial based on EBM -what are key points to generate valid evidence?]. (2004) (0)
- 2125 Evaluation timing and cutoff value of tumor size (TS) ratio by using tumor growth inhibition (TGI) model to predict overall survival (OS) in metastatic colorectal cancer (mCRC) patients received first-line chemotherapy (CTx) (2015) (0)
- Title Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial (2020) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Satoshi Morita?
Satoshi Morita is affiliated with the following schools:
